WO2022097647A1 - 統合型プラスミド - Google Patents
統合型プラスミド Download PDFInfo
- Publication number
- WO2022097647A1 WO2022097647A1 PCT/JP2021/040411 JP2021040411W WO2022097647A1 WO 2022097647 A1 WO2022097647 A1 WO 2022097647A1 JP 2021040411 W JP2021040411 W JP 2021040411W WO 2022097647 A1 WO2022097647 A1 WO 2022097647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- plasmid
- virus
- vector
- viral vector
- Prior art date
Links
- 239000013612 plasmid Substances 0.000 title claims abstract description 495
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 457
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 248
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 248
- 241000700605 Viruses Species 0.000 claims abstract description 159
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 131
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 92
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 86
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 381
- 239000013603 viral vector Substances 0.000 claims description 190
- 210000004027 cell Anatomy 0.000 claims description 182
- 102000004169 proteins and genes Human genes 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 100
- 230000010076 replication Effects 0.000 claims description 83
- 239000002245 particle Substances 0.000 claims description 64
- 241000701161 unidentified adenovirus Species 0.000 claims description 54
- 230000003612 virological effect Effects 0.000 claims description 46
- 241000711408 Murine respirovirus Species 0.000 claims description 44
- 108090000565 Capsid Proteins Proteins 0.000 claims description 39
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 39
- 241000588724 Escherichia coli Species 0.000 claims description 33
- 241000702421 Dependoparvovirus Species 0.000 claims description 28
- 210000000349 chromosome Anatomy 0.000 claims description 20
- 241000713666 Lentivirus Species 0.000 claims description 17
- 241001430294 unidentified retrovirus Species 0.000 claims description 17
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 15
- 238000011144 upstream manufacturing Methods 0.000 claims description 12
- 239000013598 vector Substances 0.000 abstract description 252
- 108020004414 DNA Proteins 0.000 description 92
- 239000012634 fragment Substances 0.000 description 75
- 210000000234 capsid Anatomy 0.000 description 44
- 108091008146 restriction endonucleases Proteins 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 230000006870 function Effects 0.000 description 28
- 230000001177 retroviral effect Effects 0.000 description 28
- 239000002585 base Substances 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 239000002609 medium Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 238000010276 construction Methods 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 22
- -1 rRNA Proteins 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000013607 AAV vector Substances 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 230000002163 immunogen Effects 0.000 description 17
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 16
- 241000193830 Bacillus <bacterium> Species 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000003623 enhancer Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 238000004806 packaging method and process Methods 0.000 description 13
- 239000007984 Tris EDTA buffer Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 230000002103 transcriptional effect Effects 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000014616 translation Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 8
- 101710172711 Structural protein Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 108091005703 transmembrane proteins Proteins 0.000 description 8
- 102000035160 transmembrane proteins Human genes 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 102100034349 Integrase Human genes 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003181 biological factor Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000008223 sterile water Substances 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 101710154606 Hemagglutinin Proteins 0.000 description 5
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
- 101710176177 Protein A56 Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000000185 hemagglutinin Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000005096 rolling process Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 4
- 229960003669 carbenicillin Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000011426 transformation method Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 3
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 108010069091 Dystrophin Proteins 0.000 description 3
- 102000001039 Dystrophin Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 3
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102100023915 Insulin Human genes 0.000 description 3
- 108020005198 Long Noncoding RNA Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091081548 Palindromic sequence Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008049 TAE buffer Substances 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000012212 insulator Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 2
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000713840 Avian erythroblastosis virus Species 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000007702 DNA assembly Methods 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714475 Fujinami sarcoma virus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091036060 Linker DNA Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 101710109576 Terminal protein Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- 125000000134 2-(methylsulfanyl)ethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])[*] 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- BMNBFRJBYVIOAY-UHFFFAOYSA-N 4,7,8-trihydroxy-3,4-dihydro-2h-isoquinolin-2-ium-1-one;chloride Chemical compound [Cl-].OC1=CC=C2C(O)C[NH2+]C(=O)C2=C1O BMNBFRJBYVIOAY-UHFFFAOYSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical group O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 1
- 102100021305 Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Human genes 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000029751 Amino acid metabolism disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 102100032948 Aspartoacylase Human genes 0.000 description 1
- 108700023155 Aspartoacylases Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241001037822 Bacillus bacterium Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102100035344 Cadherin-related family member 1 Human genes 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108700002856 Coronavirus Envelope Proteins Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 101710199711 Early E1A protein Proteins 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 108010046914 Exodeoxyribonuclease V Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018460 Feeding disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 101001042227 Homo sapiens Acyl-CoA:lysophosphatidylglycerol acyltransferase 1 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000737767 Homo sapiens Cadherin-related family member 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710096786 Lysosomal acid alpha-glucosidase Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000030162 Maple syrup disease Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000965685 Megatheriidae Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 101150118742 NP gene Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 108010015724 Prephenate Dehydratase Proteins 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 241000713711 Primate lentivirus group Species 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 102100023097 Protein S100-A1 Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000011265 Sarcospan Human genes 0.000 description 1
- 108050001531 Sarcospan Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108010064978 Type II Site-Specific Deoxyribonucleases Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229940087373 calcium oxide Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 238000001148 chemical map Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000029230 disorder of organic acid metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000024393 maple syrup urine disease Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 208000027114 metal metabolism disease Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008152 organic acidemia Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 101800000607 p15 Proteins 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000026961 psychosexual disease Diseases 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 101150066583 rep gene Proteins 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Definitions
- nucleic acid sequence encoding the capsid protein of the virus Nucleic acid sequences encoding proteins that package, transcribe, and replicate the viral genome, A plasmid of any of the above items comprising two terminal repeats of the virus and at least two of the nucleic acid sequences encoding the helper gene.
- nucleic acid sequence encoding the capsid protein of the virus Nucleic acid sequences encoding proteins that package, transcribe, and replicate the viral genome, A plasmid of any of the above items comprising two terminal repeats of the virus and at least three of the nucleic acid sequences encoding the helper gene.
- (Item A5) The nucleic acid sequence encoding the capsid protein of the virus and A nucleic acid sequence encoding a protein that packages, transcribes, and replicates the viral genome.
- (Item A6) A plasmid according to any one of the above items, wherein the nucleic acid sequence required to construct the viral vector is about 10 kb or more.
- At least one of the nucleic acid sequences encoding the capsid protein of the virus and the nucleic acid sequences encoding the proteins that transcribe and replicate the viral genome are adenovirus serum types 1-52 or adeno-related virus serum types 1-52.
- (Item A27) The plasmid of any of the above items, wherein the cap is derived from any of the adeno-associated virus serotypes 1-12 and variants thereof.
- (Item A28) A plasmid of any of the above items comprising the desired gene between two terminal repeats of the virus.
- (Item A29) The plasmid of any of the above items, wherein the desired gene is 2 to 100 genes.
- the plasmid of any of the above items, wherein the desired gene is 10 to 100 genes.
- (Item A31) A plasmid of any of the above items, wherein the desired gene comprises a promoter sequence.
- (Item A32) The plasmid of any of the above items, comprising the nucleic acid sequence required for the plasmid and the producer cells to together form the viral vector.
- (Item A33) The plasmid according to any one of the above items, wherein the amount of nucleic acid-free viral vector particles is 65% or less among all the viral vector particles produced from the producer cells into which the plasmid has been introduced.
- (Item A34) A plasmid according to any one of the above items, wherein 90% or more of all the viral vector particles produced when introduced into a producer cell contain a nucleic acid containing all desired genes.
- (Item A38) A method for producing a plasmid of any of the above items, comprising the step of operably linking any of the nucleic acid sequences of the above item.
- (Item A39) A plasmid-containing composition produced by the method according to item A38.
- (Item A40) A plasmid-containing composition according to any one of the above items, wherein the CCC (covalently closed circular) purity of the plasmid is 80% or more.
- (Item A41) A kit for preparing a plasmid of any of the above items. Nucleic acid sequences that promote plasmid replication in Bacillus subtilis, Nucleic acid sequences required to compose a virus and A kit comprising at least one nucleic acid comprising.
- At least one of the nucleic acid sequences encoding the capsid protein of the virus and the nucleic acid sequences encoding the proteins that transcribe and replicate the genome of the virus is adenovirus serotypes 1-51 or adeno-associated virus serotypes 1-51.
- a plasmid of any of the above items comprising the desired gene between two terminal repeats of the virus.
- the plasmid of any of the above items, wherein the desired gene is 2 to 100 genes.
- a plasmid of any of the above items, wherein the desired gene comprises a promoter sequence.
- (Item 20) A kit for preparing a plasmid of any of the above items. Nucleic acid sequences that promote plasmid amplification in Bacillus subtilis, Nucleic acid sequences required to compose a virus and A kit comprising at least one nucleic acid comprising.
- (Item 21) A composition for preparing a viral vector, which comprises the plasmid of any of the above items.
- (Item 22) A method for preparing a viral vector, comprising the step of producing a viral vector using any of the plasmids of the above items.
- (Item 23) A viral vector produced using any of the plasmids of the item or using any of the methods of the item.
- (Item 24) A viral vector-containing composition produced using any of the plasmids of the above item, or produced using any of the methods of the above item.
- (Item 25) The composition according to any one of the above items, wherein the amount of nucleic acid-free viral vector particles is 65% or less of all viral vector particles.
- (Item 26) The composition according to any one of the above items, wherein 90% or more of all viral vector particles contain nucleic acids containing all desired genes.
- (Item 27) The composition according to any one of the above items, wherein the amount of viral vector particles containing nucleic acid derived from the plasmid other than the desired nucleic acid is 2% or less among all the viral vector particles.
- (Item 28) Bacillus subtilis containing the plasmid of any of the above items.
- the structure of an exemplary retroviral vector plasmid constructed on the basis of pGETS103 ⁇ AarI is shown.
- the structure of an exemplary Sendai virus vector plasmid constructed on the basis of pGETS103 ⁇ AarI is shown.
- the structure of an exemplary adenovirus vector plasmid constructed on the basis of pGETS103 ⁇ AarI is shown.
- the structure and nucleic acid introduction site of the plasmid pGETS118-AarI are shown.
- the structure of an AAV virus all-in-one vector plasmid using AAV1 Rep and AAV6 Cap based on pGETS103- ⁇ AarI is shown.
- the white squares below the all-in-one structure indicate the number of unit DNAs used for construction and the approximate corresponding area.
- the structure of the AAV virus all-in-one vector plasmid using the CAG promoter based on pGETS103- ⁇ AarI, Rep of AAV5 and Cap of AAV1 is shown.
- the white squares below the all-in-one structure indicate the number of unit DNAs used for construction and the approximate corresponding area.
- the structure of the AAV virus all-in-one vector plasmid using the EF1 ⁇ promoter based on pGETS103- ⁇ AarI, Rep of AAV8 and Cap of AAV9 is shown.
- the white squares below the all-in-one structure indicate the number of unit DNAs used for construction and the approximate corresponding area.
- the structure of an AAV virus all-in-one vector plasmid in which Rep, Cap and Helper based on pGETS103- ⁇ AarI are arranged in different orders is shown. It is also an example using the SV40 promoter.
- the white squares below the all-in-one structure indicate the number of unit DNAs used for construction and the approximate corresponding area.
- Bacillus subtilis is an aerobic gram-positive catalase-positive bacterium that is ubiquitous in soil and plants and is present in the gastrointestinal tract of ruminants and humans, 0.7-0. It has a size of 8 ⁇ 2 to 3 ⁇ m, is medium temperature, has an optimum growth temperature of 25 to 40 ° C, and is said to form spores. It refers to any bacterium that is not pathogenic and has a natural transforming ability, including Bacillus licheniformis and Bacillus pumilus. In a preferred embodiment, Bacillus subtilis is Marburg 168 strain, which is a strain having high natural transformation ability in Bacillus subtilis, or RM125 strain thereof.
- the 168 strain is the most genetically studied Gram-positive bacterium, and can be obtained from ATCC (American Type Culture Collection) together with the RM125 strain. It is harmless to humans and animals, and the OGAB method can be applied. It can be suitably used in the present disclosure because it is known that it is known.
- Plasmid refers to circular DNA that exists separately from a chromosome in a cell or when introduced into a cell.
- nucleic acid sequence that promotes plasmid replication is used interchangeably with “nucleic acid sequence that promotes plasmid amplification", and when introduced into a host cell (for example, bacillus), it is inside the host cell.
- a host cell for example, bacillus
- the nucleic acid sequence that facilitates this plasmid replication is operably linked to, but not limited to, the nucleic acid sequence encoding the plasmid of interest. Details such as nucleic acid sequences that promote plasmid replication, plasmids of interest, and their relationships are described elsewhere herein.
- nucleic acid sequence that promotes plasmid replication examples include a nucleic acid sequence containing an origin of replication that operates in a target host cell (for example, Bacillus subtilis).
- a nucleic acid sequence that promotes plasmid replication in Bacillus subtilis has the ability to facilitate plasmid replication in Bacillus subtilis, but the ability to facilitate plasmid replication in non-Bacillus microorganisms (eg, E. coli). May further have.
- Nucleic acid sequences that promote plasmid replication in bacillus and other organisms are nucleic acid sequences in which the same region is utilized to promote plasmid replication in both bacillus and other organisms (eg, E.
- plasmid pSTK1 (Issay Narumt et al., BIOTECHNOLOGY LETTERS, Volume 17 No. 5 (May 1995) pp.475-480)
- plasmid pBS195 (Molekuliarnaia Genetika et al., 01 May 1991, (5): 26-29, PMID: 1896058) has been shown to be replicable in the same replication initiation region in both bacillus and E. coli, and such nucleic acid sequences are used as nucleic acid sequences to promote plasmid replication in both bacillus and E.
- subtilis Precision Protein Expression System is replicable in both E. coli and Bacillus subtilis, and such distantly located nucleic acid sequences can also be used as nucleic acid sequences that promote plasmid replication in both Bacillus subtilis and E. coli. ..
- Examples of the replication mechanism of nucleic acid (plasmid) in Bacillus subtilis include rolling circle type, theta type, oriC, and phage. Can be done.
- the rolling circle replication mechanism is a mechanism that replicates a single strand on one side of a double-stranded DNA and then replicates the other strand, because the nucleic acid exists as a single-stranded DNA for a long time.
- the plasmid tends to be destabilized.
- the theta-type replication mechanism is a mechanism in which replication of double-stranded DNA (plasmid) is started simultaneously in two directions from the origin of replication, as in the case of replication of a bacterial chromosome, and is a long DNA (for example, as disclosed in the present disclosure).
- Nucleic acid sequences that promote plasmid replication in Bacillus subtilis are sequences that are the same as or similar to known origins of replication (eg, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5). % Or more sequence identity). For example, after introducing a DNA fragment in which a candidate DNA fragment and a selection marker gene effective in Bacillus subtilis such as a drug resistance gene are linked into Bacillus subtilis, and then culturing (adding a drug or the like), this is extrachromosomal. When replicated, this candidate DNA fragment can be determined to have a nucleic acid sequence that promotes plasmid replication within Bacillus subtilis.
- a nucleic acid sequence that promotes plasmid amplification is a DNA fragment that has an origin of replication and refers to a DNA fragment that can replicate independently of chromosomal DNA. Whether or not these DNA fragments can be replicated is determined by linking these DNA fragments with a selectable marker gene such as a drug resistance gene, culturing them under selective conditions such as drugs, purifying the plasmid DNA, and electrophoring the DNA. It can be confirmed by a method such as observing the band.
- the plasmid contains a gene for the rep protein that induces the host DNA replication enzyme at the replication origin, a distribution mechanism gene for reliably distributing the plasmid to daughter cells, and a selectable marker gene. It may be included.
- the origin of replication may be fused within the gene of the rep protein.
- a viral vector refers to a structure that has at least a partial virus-derived structure and is capable of introducing nucleic acids into target cells.
- a viral vector is in the form of a viral particle containing a nucleic acid containing a viral capsid and a heterologous gene.
- oil virus refers to a virus that naturally has the virus-derived structure of a viral vector.
- the nucleic acid (carrying nucleic acid) contained in the capsid contains a gene (desired gene) sequence to be expressed in the target cell of the viral vector between two terminal repeat sequences, and in addition, a promoter and an enhancer. , Terminator and the like, or may contain a gene derived from the origin virus.
- nucleic acid sequence of a helper gene is, for example, other than the nucleic acid sequence encoding the capsid protein of the virus, the nucleic acid sequence encoding the protein that packages, transcribes and replicates the viral genome, and the two terminal repeat sequences of the virus. It may or will be essentially the nucleic acid sequence required to construct any viral vector. Each of these nucleic acid sequences can vary from viral vector to viral vector. These details are described elsewhere herein.
- the nucleic acid sequence required to construct the viral vector may utilize a favorable sequence common to AAV and adenovirus, and more preferably a sequence favorable to AAV.
- capsid refers to a protein produced from a gene carried by a virus present on the surface of a virus or viral vector (optionally enveloped), “capsid protein”. Also called. Capsids can be responsible for cell infectivity. Capsid proteins can include, but are not limited to, L2, L3, cap and gag. Although not intended to be limiting, the nucleic acid sequence encoding the viral capsid protein may be adenovirus serotypes 1-52 or adeno-associated virus serotypes 1-12, or variants thereof (rh10, DJ, DJ / 8, PHP).
- the capsid may be natural or artificially mutated.
- a product into which an "artificially mutated" has been introduced can be produced, for example, by introducing an appropriate mutation into a sequence of a natural product described in a known document.
- terminal repetitive sequence is a general term for nucleic acid sequences of biological genomes in which the same sequence is repeatedly (particularly several times or more) and is present at the terminal.
- the terminal repeat sequence include, but are not limited to, a terminal inverted repeat sequence (ITR) and a long-chain terminal repeat sequence (LTR).
- the terminal repeat sequences are adenovirus serotypes 1-52 or adeno-associated virus serotypes 1-12, or variants thereof (rh10, DJ, DJ / 8, PHP.eB, PHP.S, AAV2-retro, AAV2.
- helper gene refers to a gene that supports the amplification of a virus that cannot propagate by itself.
- helper genes include, for example, a nucleic acid sequence encoding a capsid protein of the virus, a nucleic acid sequence encoding a protein that packages, transcribes and / or replicates the viral genome, and two ends of the virus. Examples include, but are not limited to, nucleic acid sequences required to construct, multiply, enhance activity, and reduce toxicity to any viral vector other than the repeat sequence.
- helper genes examples include, but are not limited to, E1A, E1B, E2A, E2B, E4, RPE, WRPE, PPT, oPRE, enhancer, insulator, silencer sequences and the like.
- loaded nucleic acid means nucleic acid carried on a viral vector. Whether or not it is a on-board nucleic acid can be confirmed by treating the viral vector preparation with DNase to decompose the nucleic acid outside the capsid, inactivating DNase, and then confirming the nucleic acid extracted from the capsid. Whether or not it is a on-board nucleic acid can also be confirmed by examining the sequence of the obtained nucleic acid product (preferably a full length or a length close to the full length).
- nucleic acid sequences are also conservatively modified variants (eg, degenerate codon substitutions) and complementary sequences, as are the expressly indicated sequences. Is intended to be included.
- the degenerate codon substitutions create sequences in which the third position of one or more selected (or all) codons is replaced with a mixed base and / or deoxyinosine residue.
- variants based on specific wild-type sequences such as adenovirus serum types 1-52 and adeno-associated virus serum types 1-12 include known variants (eg, rh10, DJ, DJ / 8, PHP.
- deficient in a gene means that the nucleic acid does not contain the gene or exerts the normal function of the gene (eg, the function of producing a functional protein). Refers to containing a modified gene.
- operably linked is the control of a transcriptional translational regulatory sequence (eg, promoter, enhancer, etc.) or translational regulatory sequence that has expression (operation) of the desired sequence. It means that it is placed below.
- a promoter In order for a promoter to be operably linked to a gene, the promoter is usually placed immediately upstream of the gene, but it does not necessarily have to be placed adjacent to it.
- transcriptional translation regulatory sequence is a generic term for promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, replication origins, enhancers, IRES, etc., and they work together to form a recipe. Enables replication, transcription and translation of coding sequences in enhancers. Not all of these transcriptional translation regulatory sequences need to be present as long as replication, transcription and translation of the selected coding sequence is possible in a suitable host cell. Those skilled in the art can easily identify regulatory nucleic acid sequences from publicly available information. In addition, one of ordinary skill in the art can identify transcriptional translation regulatory sequences applicable to the intended use, eg, in vivo, ex vivo or in vitro.
- promoter refers to a segment of a nucleic acid sequence that controls transcription of an operably linked nucleic acid sequence.
- the promoter contains specific sequences that are sufficient for recognition, binding and transcription initiation by RNA polymerase.
- the promoter may include sequences that regulate the recognition, binding or transcription initiation of RNA polymerase.
- nucleic acid sequence refers to a segment of a nucleic acid sequence that has the function of increasing the expression efficiency of a gene of interest.
- silica refers to a segment of a nucleic acid sequence that, as opposed to an enhancer, has the function of reducing the expression efficiency of the gene of interest.
- insulator refers to a segment of a nucleic acid sequence that has the function of cis-regulating, which regulates the expression of distant genes on a DNA sequence.
- terminal refers to a segment of a nucleic acid sequence that is located downstream of the region encoding a protein and is involved in the termination of transcription as the nucleic acid is transcribed into mRNA.
- the "origin of replication” is a partial DNA double helix due to the binding of a protein that recognizes its nucleic acid sequence (eg, initiator DnaA protein, etc.) or the synthesis of RNA. Refers to the segment of the nucleic acid sequence where is unraveled and replication begins.
- homology of nucleic acids refers to the degree of identity of two or more nucleic acid sequences to each other, and in general, “homology” means a high degree of identity or similarity. say. Therefore, the higher the homology of two nucleic acids, the higher the identity or similarity of their sequences.
- stringent condition refers to a well-known condition commonly used in the art.
- the following conditions can be adopted. (1) use low ion intensity and high temperature for washing (eg, at 50 ° C., 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate), (2) during hybridization.
- the formamide concentration may be 50% or more.
- the wash time may be 5, 15, 30, 60, or 120 minutes, or longer. Multiple factors such as temperature and salt concentration can be considered as factors that affect the stringency of the hybridization reaction, and for details, refer to Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). .. Examples of "highly stringent conditions" are 0.0015M sodium chloride, 0.0015M sodium citrate, 65-68 ° C, or 0.015M sodium chloride, 0.0015M sodium citrate, and 50% formamide, 42. °C.
- sequences containing only the A sequence or only the T sequence are preferably excluded from the sequences that hybridize under stringent conditions. Moderate stringent conditions can be readily determined by one of ordinary skill in the art, eg, based on DNA length, Sambrook et al., Molecular Cloning: A Laboratory Manual, No. 3, Vol.
- polypeptides used in the present disclosure are encoded by nucleic acid molecules that hybridize under highly or moderately stringent conditions to the nucleic acid molecules encoding the polypeptides specifically described herein. Polypeptides are also included.
- a "corresponding" amino acid or nucleic acid has, or has, in a polypeptide molecule or polynucleotide molecule the same action as a given amino acid or nucleotide in a polypeptide or polynucleotide that serves as a reference for comparison.
- the corresponding amino acids are specified to be, for example, cysteineized, glutathioneified, SS bond formation, oxidation (eg, oxidation of the methionine side chain), formylation, acetylation, phosphorylation, glycosylation, myristylation, etc.
- the corresponding amino acid can be the amino acid responsible for dimerization.
- Such "corresponding" amino acids or nucleic acids may be regions or domains over a range. Thus, such cases are referred to herein as "corresponding" regions or domains.
- a "corresponding" gene eg, a polynucleotide sequence or molecule
- a gene for example, a polynucleotide sequence or a molecule
- the gene corresponding to a gene can be the ortholog of that gene.
- a serotype 1 AAV cap may correspond to a serotype 2 AAV cap.
- the corresponding gene in a virus can be found by searching the sequence database of the virus using the gene sequence of the reference virus of the corresponding gene as a query sequence.
- the term "activity" refers to the function of a molecule in the broadest sense herein. Activities are not intended to be limiting, but generally include the biological, biochemical, physical or chemical functions of the molecule.
- the activity is, for example, the enzyme activity, the ability to interact with other molecules, and the function of other molecules, which activates, promotes, stabilizes, inhibits, suppresses, or destabilizes. Includes the ability to do, stability, and the ability to localize to specific intracellular locations. Where applicable, the term also relates to the function of protein complexes in the broadest sense.
- biological function refers to a specific function that a gene, nucleic acid molecule or polypeptide may have in vivo when referring to a gene or a nucleic acid molecule or polypeptide related thereto. Examples include, but are not limited to, specific cell surface structure recognition ability, enzyme activity, binding ability to a specific protein, and the like. In the present disclosure, for example, the function of a promoter to be recognized in a specific host cell can be mentioned, but the present invention is not limited thereto. As used herein, biological function can be exerted by "biological activity”.
- biological activity refers to the activity that a certain factor (for example, polynucleotide, protein, etc.) can have in vivo, and exerts various functions (for example, transactivation activity). Activities include, for example, activities in which another molecule is activated or inactivated by interaction with one molecule. For example, if a factor is an enzyme, its biological activity comprises that enzymatic activity. In another example, if a factor is a ligand, it involves binding of that ligand to the corresponding receptor. Such biological activity can be measured by techniques well known in the art. Thus, "activity” indicates or reveals binding (either direct or indirect); affects the response (ie, has a measurable effect in response to some exposure or stimulus). Various measurable indicators, such as a measure of the amount of upstream or downstream protein in a host cell or other similar function.
- the "infectivity" of a virus or viral vector refers to the ability to introduce a virus or a nucleic acid in a viral vector into the cell by adhesion or membrane fusion of the virus or viral vector to the cell.
- the Sendai virus vector may have the same replication ability as the wild-type vector, or may be weakened by a gene mutation.
- "Replicating ability" of a virus or viral vector refers to the ability to produce infectious viral particles or viral vector particles in infected cells.
- transformation As used herein, the terms “transformation,” “transduction,” and “transfection” are used interchangeably unless otherwise noted, and introduction of nucleic acid into a host cell (virus or virus as required). Means (via vector).
- any method for introducing nucleic acid into a host cell can be used, for example, use of competent cells, electroporation method, method using a particle gun (gene gun), calcium phosphate method.
- particle gun gene gun
- calcium phosphate method Various well-known techniques such as are mentioned.
- a "purified" substance or biological factor is the removal of at least a portion of the factors naturally associated with the biological factor. Therefore, the purity of the biological factor in the purified biological factor is usually higher (ie, enriched) than in the state in which the biological factor is normally present.
- the term "purified” is preferably at least 75% by weight, more preferably at least 85% by weight, even more preferably at least 95% by weight, and most preferably at least 98% by weight. It means that the same type of biological factor is present.
- the substance used in the present invention is preferably a "purified" substance.
- the term "pharmaceutical ingredient” means any ingredient that may constitute a pharmaceutical product, for example, an active ingredient (which itself exhibits medicinal properties), an additive ingredient (which itself is not expected to have medicinal properties). However, examples thereof include components that are expected to play a certain role (for example, excipients, lubricants, surfactants, etc.) when they are contained as pharmaceuticals.
- the pharmaceutical ingredient may be a single substance or a combination of a plurality of substances or agents. Any combination may be included, such as a combination of active and additive ingredients, a combination of adjuvant and active ingredient, and the like.
- the "active ingredient” refers to an ingredient that exerts an intended medicinal effect, and may be a single ingredient or a plurality of ingredients.
- additive ingredient refers to any ingredient that is not expected to have medicinal properties but plays a certain role when it is contained as a drug, for example, a pharmaceutically acceptable carrier, a stabilizer, etc. Supplement) Auxiliary agents, solubility improvers, solubilizers, diluents, excipients, buffers, binders, diluents, flavors, and lubricants can be mentioned.
- drug As used herein, “drug”, “drug” or “factor” (both of which correspond to agents in English) are used interchangeably in a broad sense and as long as the intended purpose can be achieved. It may also be a substance or other element (eg, energy such as light, radioactivity, heat, electricity). Such substances include, for example, proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (eg, cDNA, DNA such as genomic DNA, RNA such as mRNA), poly.
- cDNA DNA such as genomic DNA
- RNA such as mRNA
- Saccharides oligosaccharides, lipids, organic small molecules (eg, hormones, ligands, signaling substances, organic small molecules, molecules synthesized with combinatorial chemistries, small molecules that can be used as pharmaceuticals (eg, small molecule ligands, etc.)) , These complex molecules and mixtures thereof include, but are not limited to.
- complex or “complex molecule” means any construct that includes two or more moieties.
- one portion is a polypeptide
- the other portion may be a polypeptide or other substance (eg, substrate, sugar, lipid, nucleic acid, other hydrocarbon, etc.). May be.
- two or more portions constituting the complex may be bonded by covalent bonds or other bonds (for example, hydrogen bonds, ionic bonds, hydrophobic interactions, van der Waals forces, etc.). It may have been done.
- label refers to an entity (eg, substance, energy, electromagnetic wave, etc.) for identifying a molecule or substance of interest from others.
- a labeling method include an RI (radioisotope) method, a fluorescence method, a biotin method, a chemiluminescence method and the like.
- the labels are labeled with fluorescent substances having different fluorescence maximum wavelengths. The difference in the maximum wavelength of fluorescence emission is preferably 10 nm or more. Any label that does not affect function can be used, but examples of the fluorescent material include Alexa TM Fluor.
- Alexa TM Fluor is a water-soluble fluorescent dye obtained by modifying coumarin, rhodamine, fluorescein, cyanine, etc., and is a series that supports a wide range of fluorescent wavelengths. It is stable, bright, and has low pH sensitivity.
- Examples of the combination of fluorescent dyes having a maximum fluorescence wavelength of 10 nm or more include a combination of Alexa TM 555 and Alexa TM 633, a combination of Alexa TM 488 and Alexa TM 555, and the like.
- Other fluorescent labels include cyanine dyes (eg, Cy3, Cy5, etc.
- such a label can be used to modify an object of interest so that it can be detected by the detection means used.
- modifications are known in the art and those skilled in the art can optionally implement such methods depending on the label and the subject of interest.
- kits refers to a unit that is usually divided into two or more sections and to which a portion to be provided (for example, a viral vector, a manual, etc.) is provided.
- the form of this kit is preferred when the purpose is to provide a composition such that it should not be mixed and provided for stability and the like, and it is preferable to mix and use immediately before use. It is preferably advantageous for such kits to include instructions or instructions describing how to use the provided parts or how to treat the reagents.
- the kit When the kit is used as a reagent kit in the present specification, the kit usually includes an instruction sheet or the like describing how to use a virus vector or the like.
- the "instruction” describes the method of using this disclosure to a doctor or another user.
- This instruction sheet contains words instructing the administration of the medicines and the like of the present disclosure.
- the instruction sheet may contain words indicating the dosage form.
- This instruction is prepared and approved by the regulatory agency of the country in which this disclosure is implemented (eg, Ministry of Health, Labor and Welfare in Japan, Food and Drug Administration (FDA) in the United States, etc.). It is clearly stated that it has been received.
- the instruction sheet is a so-called package insert, which is usually provided in a paper medium, but is not limited thereto, and is in the form of, for example, an electronic medium (for example, a homepage provided on the Internet, an e-mail). But can be provided.
- the disclosure provides a viral vector plasmid that can replicate in Bacillus subtilis. In one embodiment, the disclosure provides a viral vector plasmid that can replicate in Bacillus subtilis. Any means to achieve this is intended to be the scope of this disclosure. For example, even if there is no explicit description, the description of the method of using a certain ingredient reflects other means such as a composition containing the same ingredient, the use of the same ingredient and the same ingredient for use in the same method. The form is also intended at the same time.
- the disclosure provides a plasmid containing a nucleic acid sequence that promotes plasmid replication in bacillus and a nucleic acid sequence required to construct a viral vector.
- the nucleic acid sequence that promotes plasmid replication in Bacillus subtilis is an origin of replication that operates in Bacillus subtilis, eg, oriC, and pTB19 (Imanaka, T., et al. J. Gen. Microbioi. 130, 1399. -1408. (1984)), pLS32 (Tanaka, T and Ogra, M. FEBS Lett. 422, 243-246. (1998)), pAM ⁇ 1 (Swinfield, T.J., et al.
- Nucleic acid sequences that promote plasmid replication in Bacillus subtilis include plasmids or portions thereof, origins of replication, or variants thereof, which are known to activate the replication mechanism by rolling circle type, theta type, oriC, phage, and the like. Can be mentioned.
- the nucleic acid sequence that promotes plasmid replication in Bacillus subtilis is the same or similar sequence to a known origin of replication (eg, 90% or greater, 95% or greater, 97% or greater, 98% or greater, 99%). As mentioned above, it may have 99.5% or more sequence identity).
- the vector plasmids of the present disclosure may have promoters and / or enhancers that act on Bacillus subtilis.
- a promoter of Bacillus subtilis Pspac (Yansura, D. and Henner, D. J. Pro. Natl. Acad. Sci, USA 43, USA, 81 (1984.)), Or the Pr promoter (Itaya, M. Biosci. Biotechnol. Biochem. 63, 602-604. (1999)) and the like.
- the nucleic acid element that operates in Bacillus subtilis does not need to be derived from Bacillus subtilis, and one that operates with high efficiency can be selected.
- the origin of replication, promoter and / or enhancer operating in Bacillus subtilis in the vector plasmid is outside the region encoding the genome (which may include modifications) of the virus of origin of the viral vector or a portion thereof. Positioned.
- the vector plasmids of the present disclosure can be made or used in cells of organisms other than Bacillus subtilis and may include transcriptional translation regulatory sequences such as origins of replication, promoters, transcription termination sequences, etc. that operate in those organisms. .. Transcription-translation regulatory sequences for each organism are known and can be appropriately selected by those skilled in the art.
- the vector plasmids of the present disclosure can be made or replicated in E. coli, yeast, etc. and may include transcriptional translation regulatory sequences that operate in these microorganisms.
- the vector plasmids of the present disclosure can be introduced into a producer cell and thus may comprise a transcriptional translation regulatory sequence that operates in the producer cell.
- the vector plasmids of the present disclosure do not contain the sequences of at least some of the genes in the entire genome of the virus.
- the nucleic acid sequences required to construct the virus are located in a cohesive region on the vector plasmid.
- a vector plasmid having such a structure can be formed by incorporating a nucleic acid fragment containing a nucleic acid sequence necessary for constructing a virus into the original plasmid.
- the nucleic acid sequence required to construct the virus is about 50% or less, about 40% or less, about 30% or less, about 25% or less, about 20% or less, of the total base length of the vector plasmid. It is present in a continuous region with a base length of about 15% or less, about 10% or less, or about 5% or less.
- the sequences replicated within Bacillus subtilis may or may not be located within a contiguous region in which the nucleic acid sequences required to constitute the virus are present. ..
- elements other than the terminal repeats of the nucleic acid sequence required to constitute the virus eg, the nucleic acid sequence encoding the capsid protein of the virus, the protein that packages, transcribes and replicates the viral genome.
- One or more of the nucleic acid sequences and helper genes to be used may be located between the two end repeats or may be located on the outside.
- each element of the nucleic acid sequence required to construct the virus may be arranged in any order and position, and may be arranged in various arrangements other than those specifically shown in the drawings and the like. Is understood to be usable. If a nucleic acid sequence described for a particular function, such as a helper gene, contains multiple elements, the order and position of each element in the vector plasmid may be arbitrary, but any element (eg, VA, E2A), unless otherwise noted. , E4) may be arranged consecutively (without sandwiching another gene between them).
- the nucleic acid sequence required to construct the virus comprises the two end repeats of the virus and the base length of the region between the two end repeats (excluding the end repeats themselves). It can be about 5 kb or more, about 10 kb or more, about 20 kb or more, about 30 kb or more, about 40 kb or more, about 50 kb or more, about 70 kb or more, or about 100 kb or more.
- the nucleic acid sequence required to construct the virus comprises two end repeats and other parts of the virus, the other part outside the region sandwiched between the two end repeats. Positioned.
- the nucleic acid sequence required to construct the virus is derived from the nucleic acid sequence encoding the capsid protein of the virus (eg, cap, serum types 1-12 of adeno-associated virus or variants thereof). (Can be derived) and a nucleic acid sequence encoding a protein that packages, transcribes and replicates the viral genome (eg, rep, can be derived from either rep, adeno-associated virus serum types 1-12 or variants 8 thereof). , Two terminal repeat sequences of the virus (eg, derived from any of serum types 1-12 or variants thereof) and at least one of helper genes (eg, E1A, E1B, E2A, E4, and VA).
- helper genes eg, E1A, E1B, E2A, E4, and VA.
- the promoter, desired gene and terminator from upstream are included between the 5'ITR and the 3'ITR.
- the nucleic acid sequence encoding the viral capsid protein may be a variant of a wild-type sequence (eg, serotypes 1-12 of adeno-associated virus).
- the vector plasmids of the present disclosure contain the desired gene.
- the desired gene can be located between two terminal repeats.
- the desired gene in the vector plasmid of the present disclosure may ultimately be included in the loading nucleic acid of the viral vector.
- Such a desired gene may be encoded by a therapeutic protein, a gene for gene therapy, a gene for gene cell therapy such as CART therapy, or a gene for gene cell therapy.
- Protein non-coding functional RNAs rRNAs, tRNAs, microRNAs (miRNAs), lncRNAs, etc.
- rRNAs, tRNAs, microRNAs (miRNAs), lncRNAs, etc. may be encoded, combined with or independently of these, promoters, terminators, instructors, enhancers, silencers, replication origins, etc.
- the desired gene comprises a viral promoter such as a cytomegalovirus promoter, a CAG promoter, an SV40 promoter, an RSV promoter (optionally upstream of a protein-encoding gene).
- the desired gene comprises an IRES (optionally upstream of the protein coding gene).
- the desired gene can be integrated into the chromosome of the subject receiving the viral vector.
- the desired gene may have the function of controlling the expression of the gene inherent in the subject, or may result in long-term protein expression.
- viral vectors based on adeno-associated virus, retrovirus, etc. can be integrated into the subject's chromosomes.
- the desired gene can be integrated into a therapeutic cell (eg, a chromosome) (eg, via treatment of the cell with a viral vector in vitro).
- a therapeutic cell eg, a chromosome
- the vector plasmids of the present disclosure do not contain all the genes necessary for the virus of origin of the viral vector to grow, so that the resulting viral vector is not proliferative. It may be configured.
- the vector plasmid of the present disclosure contains about 90% or less of all viral vector particles produced from producer cells into which the plasmid has been introduced (for example, HEK293 cells) without nucleic acid. It can be about 80% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, or about 50% or less. In one embodiment, the proportion of the nucleic acid-free viral vector particles is above after freeze-thawing the producer cells three times, treating with Benzonaze at 37 ° C. for 1 hour, and centrifuging at 12500 rpm for 30 minutes.
- the vector plasmid of the present disclosure is a viral vector particle containing a nucleic acid containing all desired genes among all the viral vector particles produced when introduced into a producer cell (eg, HEK293 cell). However, it can be about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 92% or more, about 95% or more, about 97% or more, or about 99% or more.
- the vector plasmid of the present disclosure is a nucleic acid derived from the plasmid of the present disclosure other than the desired nucleic acid among all the viral vector particles produced when introduced into a producer cell (for example, HEK293 cell). Contains about 10% or less, about 7% or less, about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1.5% or less, about 1% or less, about 0. It can be 0.7% or less, about 0.5% or less, about 0.4% or less, about 0.3% or less, about 0.2% or less, or about 0.1% or less.
- the desired gene in the vector plasmid of the present disclosure may contain multiple genes.
- the desired genes are 2-100, eg, 2 or more, 3 or more, 4 or more, 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 20 or more, 25 or more, 30 or more.
- the desired gene in the vector plasmid of the present disclosure is about 0.1-1000 kbp, eg, about 0.1 kbp or higher, about 0.3 kbp or higher, about 1 kbp or higher, about 2 kbp or higher, about 5 kbp or higher, About 7 kbp or more, about 10 kbp or more, about 20 kbp or more, about 50 kbp or more or about 100 kbp or more, and about 1000 kbp or less, about 700 kbp or less, about 500 kbp or less, about 200 kbp or less, about 100 kbp or less, about 70 kbp or less, about 50
- the vector plasmid of the present disclosure can be constructed into a complex structure containing a plurality of genes by the OGAB method, a desired gene can also be constructed into a complex structure. Since the size of the on-board nucleic acid can be limited by the type of viral vector, the type of viral vector may be selected according to the size of the desired gene.
- the desired gene comprises a plurality of genes so that a subject tissue (eg, cancer tissue) -specific or time-specific promoter and a therapeutic gene operably linked thereto (eg, cancer tissue) (eg, cancer tissue).
- High functionality such as combination with therapeutic protein coding sequences, gene therapy genes, gene cell therapy genes, etc., to enable coordinated expression of a series of enzymes that control the metabolic cascade, and sequences encoding a series of enzymes. It may be possible to deliver the nucleic acid having it to the subject.
- the proteins encoded by the desired genes in the vector plasmids of the present disclosure include therapeutic polypeptides (eg, replacement therapy), immunogenic polypeptides (eg, pathogen polypeptides, cancer antigen poly). Peptide) and the like.
- therapeutic polypeptides include cystic fibrosis transmembrane control protein (CFTR), dystrophin (mini dystrophin and micro dystrophin, myostatin propeptide, follistatin, actibin type II soluble receptor, IGF-1, anti-inflammatory polypeptide.
- CFTR cystic fibrosis transmembrane control protein
- dystrophin mini dystrophin and micro dystrophin
- myostatin propeptide follistatin
- actibin type II soluble receptor IGF-1
- anti-inflammatory polypeptide anti-inflammatory polypeptide.
- Peptide growth factors Peptide growth factors, neurotrophic factors and hormones (eg, somatotropin, insulin, insulin-like growth factors 1 and 2, platelet-derived growth factors, epithelial growth factors, fibroblast growth factors, neuroproliferative factors, neurotrophic factors-3 And -4, brain-derived neurotrophic factor, bone morphogenetic protein, glia-derived growth factor, transformed growth factor- ⁇ and - ⁇ , etc.), lysosomal acid ⁇ -glucosidase, ⁇ -galactosidase A, tumor necrotizing growth factor ⁇ soluble acceptance Body, S100A1, parbualbumin, adenylylcyclase type 6, anti-inflammatory factors, antimyostatin proteins, aspartoacylase, suicide gene products (eg, thymidine kinase, cytosine deaminase, diphtheria toxins, tumor necrotizing factors), tumor suppressor genes Products (eg, p53, Rb, Wt-1),
- pathogen polypeptides include cell surface proteins of pathogens such as bacteria, fungi, and parasites, and proteins expressed on the surface of viruses (for example, spike proteins, envelope proteins, capsid proteins, etc.).
- pathogen polypeptide include orthomyxovirus immunogens (eg, influenza virus hemagglutinin (HA), nuclear protein), lentiviral immunogens (eg, HIV or SIV envelope GP160 protein, matrix / capsid protein, gag, etc.).
- orthomyxovirus immunogens eg, influenza virus hemagglutinin (HA), nuclear protein
- lentiviral immunogens eg, HIV or SIV envelope GP160 protein, matrix / capsid protein, gag, etc.
- pol, envelope gene product eg, Lassa fever virus nuclear capsid protein, enveloped glycoprotein
- poxvirus immunogen eg, Wakusina L1 or L8 gene product
- flavivirus immunogen eg, yellow fever
- phyllovirus immunogen eg, Ebola virus or Marburg virus immunogen such as NP and GP gene products
- bunyavirus immunogen eg, RVFV, CCHF, SFS virus immunogen
- coronavirus Immunogen eg, human coronavirus immunogen such as human coronavirus envelope glycoprotein
- polio immunogen eg, herpesvirus immunogen (eg, CMV, EBV, HSV immunogen)
- mumpsvirus immunogen measles virus immunogen
- Examples include ruin virus immunogens, diphtheria toxins or other diphtheria immunogens, pertussis antigens, and hepatitis (eg, hepatitis A, hepatitis A, he
- BRCA1 gene product As cancer antigen polypeptides, BRCA1 gene product, BRCA2 gene product, gp100, tyrosinase, GAGE-1 / 2, BAGE, RAGE, LAGE, NY-ESO-1, CDK-4, ⁇ -catenin, MUM-1, caspase.
- the desired gene can be a gene for treating a particular disease (eg, a gene therapy gene).
- a gene therapy gene e.g. a gene therapy gene.
- the gene to be selected for a specific disease can be appropriately selected by those skilled in the art.
- diseases include, for example, infections caused by various pathogens, cystic fibrosis, hemophilia A, hemophilia B, salacemia, anemia, Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, and muscle atrophy.
- the vector plasmids of the present disclosure are used to produce viral vectors.
- the disclosure provides a method of making a viral vector using the vector plasmids of the present disclosure.
- the present disclosure provides a viral vector-containing composition or viral vector thus prepared.
- Viral vectors include viral vectors based on retrovirus, lentivirus, adeno-associated virus, adenovirus or Sendai virus.
- the vector plasmids of the present disclosure are introduced into producer cells to produce viral vectors.
- producer cells include, for example, 911 cells, PER. C6 cells, E1 transformed sheep membrane cells, E1 transformed A549 cells, GH329: HeLa cells, HEK293 cells, IT293SF cells, HEK293T, HEK293F, Vero cells, CHO cells, Sf9 cells, Freestyle TM 293-F, Expi293-F (Trademark), Expi293 inducible, Expi293 NGT-Viral Production Cells 1.0, Viral Production Cells 2.0, AAVpro (registered trademark) 293T CellLine, Lenti-X (trademark) 293Tle (trademark) 293T Examples include, but are not limited to, cells, ExpiCHO-S TM, and the like.
- the vector plasmids of the present disclosure lack a small number (eg, one, two, three, four, or five) of the genes of the virus of origin of the viral vector and all others. May contain the gene of.
- the vector plasmids of the present disclosure lack a portion of the gene set required to produce a viral vector, and the gene lacking the vector plasmid in the gene set is a gene.
- Vector plasmids are supplied to trans in producer cells.
- the vector plasmids of the present disclosure may enable viral vector production by being introduced alone into producer cells without combination with other plasmids.
- the vector plasmids of the present disclosure can be introduced into producer cells expressing all genes lacking the vector plasmid in the gene set required to produce a viral vector.
- the vector plasmids of the present disclosure containing caps and rep of AAV and E2A, E4 and VA of adenovirus can alone produce viral vectors by introduction into HEK293 cells expressing adenovirus E1A and E1B. ..
- the vector plasmid of the present disclosure is produced with another nucleic acid containing a gene lacking the vector plasmid in the gene set required to produce a viral vector or a product of the gene (eg, viral particles). Can be introduced into cells.
- a viral vector can be made by introducing a vector plasmid into a producer cell infected with the virus of origin of the viral vector and causing homologous recombination in the cells.
- the viral vector plasmid used in this embodiment comprises a nucleic acid sequence having homology to any region (eg, intergenic region) of the genome of the desired gene and the virus of origin.
- the vector plasmid may have a structure containing the desired gene between any genes in the genome of the virus of origin of the viral vector produced.
- at least a portion of the nucleic acid contained in the vector plasmid is integrated into the chromosome of the producer cell.
- the vector plasmid of the present disclosure comprises a segment for excision of the carrying nucleic acid of the virus of origin of the virus vector produced (LTR in retrovirus, ITR in AAV virus, etc.), and in one embodiment, this. Contains the desired gene between the segments.
- the vector plasmids of the present disclosure are operable in a target gene targeted by a viral vector, such as a promoter and / or termitator operably linked to the desired gene between the segments. )including.
- the vector plasmids of the present disclosure do not contain the genes required for viral replication of origin of the viral vector between these segments.
- the vector plasmid of the present disclosure comprises a packaging signal of the virus of origin of the viral vector produced.
- the viral vector produced has a capsid, which can be involved in binding to tissues or cells. Therefore, the targeting of the viral vector to the tissue or cell can be adjusted by modifying the capsid to modify the binding property to the tissue or cell (or its surface structure).
- the vector plasmids of the present disclosure may have a gene encoding a capsid, which capsid may be modified.
- other proteins eg, other viral capsids (eg, capsids of other serum types of viruses, VSV-G), antigen-binding regions of antibodies, ligands of subject organisms, as capsid modifications that regulate tissue or cell targeting. Substitution or fusion with a protein (such as a ligand for a cancer antigen).
- the viral vector having an envelope may contain the cell membrane component of the producer cell in the envelope. Therefore, by modifying the cell membrane component of the producer cell, the targeting of the enveloped viral vector to the tissue or cell can be adjusted.
- the viral vector is a nerve cell (such as a peripheral or central nervous system cell, a brain cell such as a neuron and oligodendrosite), a lung cell, an eye cell (retinal cell, retinal pigment epithelium, corneal membrane).
- epithelial cells eg, intestinal or respiratory epithelial cells
- muscle cells eg, skeletal muscle cells, myocardial cells, smooth muscle cells, diaphragmatic muscle cells
- dendritic cells pancreatic cells (islet cells, etc.)
- myocardial cells bone cells (eg, bone marrow stem cells), hematopoietic stem cells, spleen cells, keratinocytes, fibroblasts, endothelial cells, prostate cells, germ cells, cancer cells, etc. May be good.
- Surface structures specific to each cell are known, and one of ordinary skill in the art can appropriately select a protein that strongly or specifically binds to the surface structure.
- the vector plasmid of the present disclosure may contain a gene encoding a protein that is an attenuated protein of the origin virus of the viral vector produced.
- the vector plasmids of the present disclosure can contain genes encoding any known attenuated viral proteins.
- the present disclosure provides a plasmid-containing composition comprising a population of vector plasmids of the present disclosure.
- the plasmid-containing composition has a plasmid CCC (covalently closed circular) purity of about 60% or higher, about 70% or higher, about 75% or higher, about 80% or higher, about 85% or higher, about 90. It can be greater than or equal to% or greater than or equal to about 95%.
- Adenovirus is a virus belonging to the genus Mustadenovirus of the family Adenovirus family, and the virus particles are composed of nucleocapsid and a double-stranded linear DNA genome and have a regular 20-hedron structure of 90 to 100 nm.
- Infection with adenovirus is initiated by the adsorption of the viral capsid on the coxackie-adenovirus receptor (CAR) on the cell surface, which can then be initiated by the virus via cell surface integrin.
- CAR coxackie-adenovirus receptor
- the viral genome that escapes from the lysosome can then reach the nucleus and result in replication of the viral genome.
- Viral replication is initiated by first expressing the E1A protein and then activating the expression of other early proteins, E1B, E2, E3, E4.
- the terminal protein (TP) expressed from E2 is covalently bound to deoxycytidine, and a complex to which a polymerase is further bound is formed to initiate replication.
- the genome also encodes structural proteins, including penton (L2), hexons (L3), skeletal proteins (L4), and fibrous proteins (L5), and is under the control of a single promoter, with five late transcription units (L1). , L2, L3, L4, and L5). Both ends of the genome contain inverted terminal repeats (ITRs) required for viral replication.
- ITRs inverted terminal repeats
- Adenovirus After being translated in the cytoplasm, viral structural proteins migrate into the nucleus to form viral particles, recognize the packaging signal ( ⁇ ) of the viral genome, and package the genome. Adenovirus also produces protein non-encoding VA RNA, which is encoded by the VA gene. Adenovirus particles may have L2 and L3 capsids.
- subgroup A eg, serotypes 12, 18 and 31
- subgroup B eg, serotypes 3, 7, 11, 14, 16, 21, 34, 35 and 50
- subgroup C eg, serotypes 1, 2, 5 and 6
- subgroup D eg, serotypes. 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39 and 42-48
- subgroup E eg, serotype 4
- subgroup F eg, eg. They are classified into serotypes 40 and 41
- unclassified serotype groups eg, serotypes 49 and 51).
- the adenoviral vector plasmid contains at least one of the nucleic acid sequences required to construct the adenoviral vector and the desired gene. In one embodiment, the adenoviral vector plasmid contains the desired gene between 5'ITR and 3'ITR. In one embodiment, the adenoviral vector plasmid contains the desired gene, promoter and terminator between the 5'ITR and the 3'ITR. In one embodiment, the adenoviral vector plasmid does not contain one or more (eg, all) of the nucleic acid sequences required to construct the adenoviral vector between the 5'ITR and the 3'ITR.
- the adenovirus vector plasmid is configured to function in a producer cell such that the vector plasmid and the producer cell contain the nucleic acid sequences necessary to construct the adenovirus vector.
- one or more (eg, all) of the nucleic acid sequences required to construct an adenovirus vector that are not included in the vector plasmid may be encoded on the chromosome of the producer cell. good.
- the nucleic acid sequence required to construct an adenoviral vector is a gene encoding E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4, L5, IX, IVa2.
- the nucleic acid sequence required to construct an adenovirus vector can be all genes of adenovirus other than E3.
- the nucleic acid sequences required to construct an adenovirus vector are a nucleic acid sequence encoding a capsid protein (L2, L3) and a nucleic acid sequence encoding a protein that packages, transcribes and replicates the genome (L2, L3).
- E1A, E1B, E2A, E2B, E4), two terminal repeat sequences (5'ITR, 3'ITR), and a nucleic acid sequence of a helper gene may be included.
- the nucleic acid sequence of the helper gene can be any adenovirus gene except L2, L3, E1A, E1B, E2A, E3, E2B, E4, 5'ITR, 3'ITR.
- the adenoviral vector plasmid may be free of one or more of VA, E1A, E1B, E2A, E2B, E4 and constitutes an adenoviral vector in one embodiment. Nucleic acid sequences required for these include these.
- the adenoviral vector plasmid is free of E1A and E1B.
- the adenovirus vector plasmid is deficient in E1A and the desired gene may be inserted at this deficient site.
- VA RNA is known to interact with exportin, RISK, Dicer, etc. in humans, and by deleting VA from an adenoviral vector plasmid, side effects on adenovirus vector-infected cells can be reduced. Since E1A, E1B, E2A, E2B, and E4 can be genes required for adenovirus replication, an adenovirus vector plasmid lacking them can reduce the replication ability in infected cells.
- the adenovirus vector of the present disclosure can be derived from human subgroup C, eg, serotype 2 or serotype 5.
- the adenovirus vectors of the present disclosure are serotype 12 (subgroup A), serotype 7 or serotype 35 (subgroup B), serotype 30 or serotype 36 (subgroup D), serotype. It can be derived from 4 (subgroup E) or serotype 41 (subgroup F).
- producer cells for producing an adenovirus vector include cells such as HEK293, HEK293T, HEK293F, Hela, and Sf9.
- Adeno-associated virus is a linear single-stranded DNA virus belonging to the genus Dependoparvovirus of the family Parvovirus, and the virus particles have a diameter of 20 to 26 nm. Adenovirus elements are required for AAV growth. At the end of the AAV genome, there is a T-shaped hairpin structure called the ITR (inverted periodic repeat). This portion of the ITR serves as the starting point for replication and acts as a primer. This ITR is also required for packaging into virus particles and integration into chromosomal DNA of host cells.
- rep gene encoding a non-structural protein, that is, a regulatory protein (Rep78, Rep68, Rep52, Rep40) that controls replication and transcription
- structural protein VP1, VP2, VP3
- cap genes encoding three capsid proteins.
- the life cycle of AAV is divided into latent infection and lytic infection.
- the former is the case of infection alone, and is characterized by being integrated into the AAVS1 region (19q13.3-qter) of the long arm of chromosome 19 of the host cell. This integration is due to illegitimate recombination and Rep is involved.
- Rep78 / Rep68 binds to a base sequence (GAGC repeat sequence) that is commonly present in the AAVS1 region and the Rep-binding region of ITR. Therefore, when wild-type AAV infects target cells, it is considered that Rep binds to ITR and AAVS1 of AAV, and the intervention of Rep causes site-specific integration of the AAV genome into chromosome 19. Has been done.
- helper virus such as adenovirus
- AAV replication occurs when the cells latently infected with AAV are further infected with Helver virus, and a large amount of virus is released by cell destruction (lytic infection). ..
- the AAV vector plasmid contains at least one of the nucleic acid sequences required to construct the AAV vector and the desired gene. In one embodiment, the AAV vector plasmid contains the desired gene between 5'ITR and 3'ITR. In one embodiment, the AAV vector plasmid contains the desired gene, promoter and terminator between the 5'ITR and the 3'ITR. In one embodiment, the AAV vector plasmid does not contain one or more (eg, all) of the nucleic acid sequences required to construct the AAV vector between the 5'ITR and the 3'ITR.
- the AAV vector plasmid is configured to function in a producer cell such that the vector plasmid and the producer cell contain the nucleic acid sequences necessary to construct the AAV vector.
- one or more (eg, all) of the nucleic acid sequences required to construct an AAV vector that are not included in the vector plasmid may be encoded on the chromosome of the producer cell. ..
- the nucleic acid sequences required to construct the AAV vector are 5'ITR, rep, cap, AAP (assembly-activated protein), MAAP (membrane-associated accessory protein) and 3'ITR of AAV, as well. It can be the adenoviruses E1A, E1B, E2A, VA and E4.
- the nucleic acid sequences required to construct the AAV vector are the nucleic acid sequence encoding the AAV capsid protein (cap) and the nucleic acid sequence encoding the AAV protein that packages, transcribes and replicates the genome (rep).
- AAV vector plasmid may be free of one or more of rep, cap, VA, E1A, E1B, E2A, E4 and constitutes an adenovirus vector in one embodiment.
- the nucleic acid sequences required for this include these.
- AAV has been reported to have serotypes 1-12 based on capsid.
- Serotypes of 74, AAV2.5, AAV-TT, and Anc80 have also been reported.
- the AAV vectors of the present disclosure may be made based on a suitable serotype of AAV depending on the target tissue.
- the relationship of (serotype): (target tissue) may be selected as follows; (AAV1): (muscle, liver, airway, nerve cell), (AAV2): (muscle, liver, nerve cell).
- AAV3 (muscle, liver, nerve cell), (AAV4): (muscle, ventricular coat cell), (AAV5): (muscle, liver, nerve cell, glial cell, airway), (AAV6): (Muscle, liver, airway, nerve cell), (AAV7) :( muscle, liver), (AAV8): (muscle, liver), (AAV9): (muscle, liver, airway).
- producer cells for producing an AAV vector include cells such as HEK293, HEK293T, HEK293F, Hela, and Sf9.
- AAV capsids in addition to wild-type capsids, capsids with targeted mutations (AAV2i8, AAV2.5, AAV-TT, AAV9.HR, etc.), capsids with random mutations (AAV-PHP.B, etc.), Capsids designed with Incilico (such as Anc80) may be mentioned, and in one embodiment the AAV vectors of the present disclosure may contain these modified capsids, as the AAV vector plasmids of the present disclosure encode these modified capsids. May be constructed.
- retrovirus generally refers to a virus of the family Retrovirus family.
- Torovirus is a double-stranded RNA enveloped virus characterized primarily by the ability to reverse-transcribe the genome from RNA to DNA.
- the virion is about 100-120 nm in diameter and contains the dimeric genome of the same plus RNA strand complexed with the nucleocapsid protein.
- the genome is encapsulated in a capsid containing the enzyme proteins required for viral infection, namely reverse transcriptase, integrase and protease.
- the matrix protein forms the outer layer of the capsid core that interacts with the envelope, which is a lipid bilayer derived from the host cell membrane that surrounds the viral nucleus particles. This bilayer is immobilized with viral envelope glycoproteins that recognize specific receptors on host cells and initiate the infectious process. Envelope proteins are formed by two subunits, a transmembrane protein (TM) that anchors the protein within the lipid membrane and a surface (SU) that binds to cell receptors.
- TM transmembrane protein
- SU surface
- mouse leukemia virus MMV
- human immunodeficiency virus HAV
- horse infectious anemia virus EIAV
- mouse breast tumor virus MMTV
- Rous sarcoma virus RSV
- Fujinami sarcoma virus FuSV
- Moloney mouse leukemia virus Mo-MLV
- FBR MSV FBR mouse osteosarcoma virus
- Mo-MSV Abelson mouse leukemia virus
- MC29 avian myelodystrophy virus 29
- AEV avian erythroblastosis virus
- lentivirus lentivirus
- Lentiviruses can be divided into “primates” and “non-primates”.
- primate lentiviruses include human immunodeficiency virus (HIV), which is the causative agent of human acquired immunodeficiency syndrome (AIDS), and simian immunodeficiency virus (SIV).
- the non-primate lentivirus group includes the prototype "delayed virus” Bisna / Maedivirus (VMV), as well as related goat arthritis encephalitis virus (CAEV), horse infectious anemia virus (EIAV), and more recently. Includes feline immunodeficiency virus (FIV), and bovine immunodeficiency virus (BIV).
- retroviruses During the infectious process, retroviruses first attach to specific cell surface receptors. Upon invasion of a susceptible host cell, the retroviral RNA genome is copied into DNA by reverse transcriptase. This DNA is transported to the host cell nucleus and then integrated into the host genome, a condition called a provirus. Proviruses are stable on host chromosomes during cell division and are transcribed like other cellular proteins. Proviruses encode the proteins and packaging mechanisms required to make more viruses and are capable of budding and leaving cells. When retroviruses emerge from host cells, they contain host cell lipid membranes. In this way, the host cell-derived membrane protein becomes part of the retroviral particles.
- the retrovirus genome contains four genes: gag (group-specific antigen), pro (protease), pol (polymerase) and env (envelope).
- gag sequence encodes three major structural proteins: matrix protein, nucleocapsid protein, and capsid protein.
- the pro sequence encodes a protease responsible for cleaving Gag and Gag-Pol during particle assembly, budding and maturation.
- the pol sequence encodes reverse transcriptase and integrase enzymes, the former catalyzing reverse transcription of the viral genome from RNA to DNA during the infectious process, the latter processing LTR and hosting provirus DNA. It plays a role in incorporating into the cell genome.
- the env sequence encodes both the SU and TM subunits of the enveloped glycoprotein.
- the ability of a retrovirus to bind to its target host cell using a specific cell surface receptor is conferred by the surface component (SU) of the Env protein, whereas the ability of the retrovirus to enter the cell via a membrane fusion. , Can be imparted by a membrane anchor type transmembrane component (TM).
- the retroviral genome contains elements necessary to promote gene expression, reverse transcription and integration into host cell chromosomes, as these elements are two LTRs (long terminal repeats), viruses to newly formed virions.
- PPT polypurine tract
- the sex sequence is mentioned.
- the long terminal repeat (LTR) is about 600 nt in length, of which the U3 region is 450 nt, the R sequence is 100, and the U5 region is approximately 70 nt.
- the genome of complex retroviruses such as lentivirus may contain, in addition to gag, pro, pol and envelope, accessory genes that regulate viral gene expression, assembly of infectious particles and modulate viral replication in infected cells.
- a typical lentivirus is HIV-1.
- Lentiviruses may contain two regulatory genes, tat and rev.
- HIV-1 further comprises vif, vpr, vpu and nef.
- accessory genes such as vpx.
- These accessory genes are involved in the synthesis and processing of viral RNA as well as the regulation of other replication functions.
- HIV also includes structural landmarks (TAR, RRE, PE, SLIP, CRS, INS) and the like.
- Lentiviral particles may contain the capsid protein of p24.
- the retroviral vector plasmid contains at least one of the nucleic acid sequences required to construct the retroviral vector and the desired gene. In one embodiment, the retroviral vector plasmid contains the desired gene between the 5'LTR and the 3'LTR. In one embodiment, the retroviral vector plasmid may include a primer binding site (PBS) and / or a polyprint lacto (PPT) between the 5'LTR and the desired gene. In one embodiment, the retroviral vector plasmid may contain a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) between the desired gene and the 3'LTR.
- PBS primer binding site
- PPT polyprint lacto
- the retroviral vector plasmid may contain a Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) between the desired gene and the 3'LTR.
- WPRE Woodchuck hepatitis virus post-transcriptional regulatory element
- the retroviral vector plasmid is configured to function in a producer cell such that the vector plasmid and the producer cell contain the nucleic acid sequences necessary to construct the retroviral vector.
- one or more (eg, all) of the nucleic acid sequences required to construct a retroviral vector that are not included in the vector plasmid may be encoded on the chromosome of the producer cell. good.
- env may be replaced with a gene encoding VSV-G (glycoprotein G of vesicular stomatitis virus (VSV)) during the construction of the retroviral vector.
- VSV-G glycoprotein G of vesicular stomatitis virus
- the retroviral vector (including lentivirus) plasmid may additionally contain the VSV-G gene.
- the glycoprotein gene (RV-G) or RV-G intracellular domain of the mad dog disease virus in addition to or in place of env, the glycoprotein gene (RV-G) or RV-G intracellular domain of the mad dog disease virus.
- a fusion glycoprotein (FuG-B) in which is replaced with that of a water-foaming stomatitis virus glycoprotein (VSV-G) may be used, and the retroviral vector (including lentivirus) plasmid may contain these genes. good.
- the nucleic acid sequences required to construct a retroviral vector are a nucleic acid sequence encoding a capsid protein (gag) and a nucleic acid sequence encoding a protein that packages, transcribes and replicates the genome (pol). And two terminal repeat sequences (5'LTR, 3'LTR) and the nucleic acid sequence of the helper gene.
- the nucleic acid sequence of the helper gene can be a packaging signal ( ⁇ ) sequence, pro, pol and env.
- the retroviral vector plasmid may be free of one or more of gag, pro, pol, env, and in one embodiment, the nucleic acids required to construct the retroviral vector. The sequence contains these.
- the retroviral vector plasmid does not contain one or more (eg, all) of the nucleic acid sequences required to construct the retroviral vector between the 5'LTR and 3'LTR.
- the retroviral vector plasmid contains the desired gene between the 5'LTR and the 3'LTR.
- the retroviral vector plasmid contains the desired gene, promoter, and terminator between the 5'LTR and 3'LTR.
- the retroviral vector plasmid may be modified to lack the U3 region of the LTR. Examples of producer cells for producing a retroviral vector include cells such as HEK293T.
- the nucleic acid sequences required to construct a lentiviral vector are a nucleic acid sequence encoding a capsid protein (gag) and a nucleic acid sequence encoding a protein that packages, transcribes and replicates the genome (pol, It may contain a rev, a packaging signal ( ⁇ ) sequence, at least one of APP, MAAP), two terminal repeat sequences (5'LTR, 3'LTR), and a nucleic acid sequence of a helper gene.
- the nucleic acid sequence of the helper gene can be pro, pol and env.
- the lentiviral vector plasmid may be free of one or more of rev, gag, pro, pol, env and is required to construct the lentiviral vector in one embodiment. Nucleic acid sequences include these. Since pol and rev can be genes required for lentivirus replication, lentiviral vector plasmids lacking them can reduce their replication ability in infected cells. In one embodiment, the lentiviral vector plasmids are tar, vif, vpr, vpu, nef, vpx, TAR, RRE, PE, SLIP, CRS, INS, APP, MAAP, RPE, PPT, PRE, WRPE, oPRE. One or more of them may be included.
- the lentiviral vector plasmid does not contain one or more (eg, all) of the nucleic acid sequences required to construct the lentiviral vector between the 5'LTR and 3'LTR.
- the lentiviral vector plasmid contains the desired gene between the 5'LTR and 3'LTR.
- the lentiviral vector plasmid contains the desired gene, promoter, terminator, and WPRE between the 5'LTR and 3'LTR.
- the lentiviral vector plasmid may be modified to lack the U3 region of the LTR, the TAT.
- the retroviral vector plasmid may be modified to lack the U3 region of the LTR. Examples of producer cells for producing a lentiviral vector include cells such as HEK293T, HEK293, and Hela.
- Sendai virus is a minus-strand RNA virus classified into the genus Respirovirus of the family Paramyxoviridae. Sendai virus can also infect non-dividing cells, including neurons. After infection with Sendai virus, the viral genome does not integrate into the chromosomes of the host cell and remains in the cytoplasm in the form of RNA.
- Examples of the gene encoding the Sendai virus protein include N, P, M, F, HN and L genes.
- the N, P, M, F, HN and L genes encode nucleocapsids, phospho, matrix, fusion, hemagglutinin neuraminidase and large proteins, respectively.
- Six genes encoding (hemagglutinin / noiraminidase) and L (large protein) are lined up, with a short 5'trailer region (TR) at the other end.
- Accessory proteins called C and V are also translated from the region of the P gene.
- Sendai virus expresses genes by both tubulin and Sendai virus RNA polymerase (L protein) in the cytoplasm of host cells. Sendai virus does not interact with the host cell genome and is not pathogenic to humans. These characteristics of Sendai virus suggest the safety of Sendai virus vector to humans.
- M proteins, F proteins, and HN proteins can be responsible for the formation of viral particles and viral infection of Sendai virus.
- N-proteins, P-proteins and L-proteins can be responsible for the expression and replication of the viral genome.
- the nucleic acid transcribed from the Sendai virus vector plasmid in the producer cell becomes the loading nucleic acid of the Sendai virus vector. Therefore, the following characteristics of the Sendai virus vector plasmid may also be the characteristics of the nucleic acid loaded on the Sendai virus vector.
- the Sendai virus vector plasmid contains at least one of the nucleic acid sequences required to construct the Sendai virus vector and the desired gene.
- the desired gene can be located upstream and / or downstream of any of the Sendai virus genes (N, P, M, F, HN and L genes).
- the Sendai virus vector plasmid can contain an EIS sequence (transcriptional termination (E) sequence-intervening (I) sequence-transcription initiation (S) sequence) upstream or downstream of the desired gene, so that This can promote the expression of genes upstream or downstream of the desired gene.
- EIS sequence transcriptional termination (E) sequence-intervening (I) sequence-transcription initiation (S) sequence
- the Sendai viral vector plasmid can be modified to insert a sequence having multiples of 6 bases (eg, a sequence containing the desired gene).
- the Sendai virus vector plasmid is configured to function in a producer cell such that the vector plasmid and the producer cell contain the nucleic acid sequences necessary to construct the Sendai virus vector.
- one or more (eg, all) of the genes or gene products thereof that are not included in the vector plasmid among the nucleic acid sequences required to construct the Sendai virus vector are produced in the vector plasmid and trans. Can be supplied in cells.
- the nucleic acid sequences required to construct the Sendai virus vector are the nucleic acid sequence encoding the capsid protein (N, HN) and the nucleic acid sequence encoding the protein that packages, transcribes and replicates the genome (N, HN). It may contain P, L), two terminal sequences (LE, TR), and a nucleic acid sequence of a helper gene.
- the nucleic acid sequence of the helper gene can be F, V, C and M.
- the nucleic acid sequence required to construct the Sendai virus vector can be all genes of Sendai virus.
- the Sendai virus vector plasmid contains the nucleic acid sequences required to construct Sendai virus between LE and TR.
- the nucleic acid sequence required to construct the Sendai viral vector may comprise the genes N, P, V, C, M, F, HN, L.
- the nucleic acid sequence required to construct the Sendai virus vector can be all genes of Sendai virus other than one or more of M, F and HN.
- the on-board nucleic acid may lose transmissibility in the host.
- the Sendai viral vector plasmid may be free of one or more of M, F and HN, and in one embodiment the nucleic acid sequence required to construct the Sendai viral vector Including these.
- the Sendai viral vector plasmid may contain a gene encoding the RNA polymerase of bacteriophage T7. In one embodiment, the Sendai virus vector plasmid may contain a self-cleaving ribozyme Rbz.
- the Sendai virus gene may be modified to reduce the antigenicity of the Sendai virus protein or to increase the transcription efficiency and replication efficiency of RNA.
- one or more of the replication factors N, P and L genes may be modified to enhance transcriptional or replication function.
- the structural protein HN protein may be modified so that hemagglutinin activity and / or neuraminidase activity can be altered and weakening hemagglutinin activity reduces viral stability in the blood. It can be improved and the infectivity of the virus can be changed by changing the neuraminidase activity.
- the F protein involved in membrane fusion may be modified. In one embodiment, it may be modified to delete the V gene, which is an accessory gene. Examples of producer cells for producing the Sendai virus vector include cells such as BHK / T7.
- the present disclosure provides a viral vector-containing composition comprising a population of viral vectors of the present disclosure.
- the viral vector-containing composition comprises about 90% or less, about 80% or less, about 75% or less, about 70% or less, about 65 of all viral vector particles containing no nucleic acid. % Or less, about 60% or less, about 55% or less, or about 50% or less.
- the viral vector-containing composition of the present disclosure contains about 75% or more, about 80% or more, about 85% of all viral vector particles containing nucleic acids containing all desired genes. % Or more, about 90% or more, about 92% or more, about 95% or more, about 97% or more, or about 99% or more.
- the viral vector-containing composition of the present disclosure contains about 10% or less, about 7% of all viral vector particles containing nucleic acids derived from the plasmids of the present disclosure other than the desired nucleic acids. Below, about 5% or less, about 4% or less, about 3% or less, about 2% or less, about 1.5% or less, about 1% or less, about 0.7% or less, about 0.5% or less, about 0 It can be 0.4% or less, about 0.3% or less, about 0.2% or less, or about 0.1% or less.
- the disclosure provides a method of making a vector plasmid of the present disclosure, comprising the step of operably linking multiple nucleic acid sequences. In one embodiment, the disclosure provides a method of making a vector plasmid of the present disclosure comprising replicating the vector plasmid of the present disclosure in Bacillus subtilis. In one embodiment, the present disclosure is a step of introducing into a host cell a nucleic acid comprising a nucleic acid sequence for producing a viral vector having a sequence that is replicated within the bacillus to form a plasmid in said host cell. Provided is a method for producing the vector plasmid of the present disclosure, which comprises.
- Bacillus subtilis may have the ability to form a plasmid from an externally taken up nucleic acid, so the nucleic acid to be introduced in this method does not have to be a plasmid.
- Bacillus subtilis can take up this nucleic acid and form a plasmid within Bacillus subtilis when in contact with a nucleic acid (eg, an acyclic nucleic acid having a tandem repeat nucleic acid sequence) (eg, the OGAB method described herein). checking).
- a nucleic acid eg, an acyclic nucleic acid having a tandem repeat nucleic acid sequence
- the method of introducing nucleic acid into Bacillus subtilis can be any method, for example, the use of competent Bacillus subtilis, the electroporation method, the method using a particle gun (gene gun), calcium phosphate.
- the law etc. can be mentioned.
- "Competent” refers to a state in which a cell becomes more permeable to an exogenous substance (eg, nucleic acid). Any known method can be used to make Bacillus subtilis competent, and for example, Anagnostopoulou, C.I. And Spiriten, J.M. J. Bacteriol. , 81, 741-746 (1961).
- the vector plasmids of the present disclosure may be made in Bacillus subtilis and amplified in the same Bacillus subtilis as is.
- the nucleic acid to be introduced may contain each element of the viral vector plasmid described in detail below.
- the vector plasmids of the present disclosure can be made by the OGAB method.
- the OGAB (Ordered Gene Assembly in Bacillus subtilis) method is a method for producing a circular plasmid in a transformed organism by incorporating the accumulated nucleic acid into the transformed organism.
- the OGAB method does not necessarily require the use of Bacillus subtilis, any organism capable of incorporating acyclic long-stranded nucleic acids and producing a plasmid can be used, such organisms being "transformed" herein. Called "living organism”.
- a plasmid containing a large-sized nucleic acid can be easily prepared.
- Nucleic acid to be incorporated into a transforming organism is referred to herein as "accumulated nucleic acid," and typically the integrated nucleic acid is a tandem repeat in which one unit of plasmid and one set of unit nucleic acid appear repeatedly in the same direction.
- the term "unit nucleic acid” refers to a nucleic acid molecule or a portion of a nucleic acid molecule having a partial sequence constituting the sequence of an integrated nucleic acid, and as described in detail below, a plurality of types of unit nucleic acids are used. It is prepared as a unit vector, after which an integrated nucleic acid is constructed.
- unit nucleic acid for incorporation into integrated nucleic acid.
- the unit nucleic acid can be prepared by any known method, for example, by polymerase chain reaction (PCR) or chemical synthesis.
- a unit nucleic acid is a sequence encoding a desired protein (therapeutic protein, a protein constituting a viral vector, etc.) or a portion thereof, a sequence for controlling a gene (promoter, enhancer, etc.), and a sequence for manipulating the nucleic acid (restriction enzyme). It may have any desired sequence, such as a recognition sequence).
- the ends of each unit nucleic acid may be configured to give rise to a specific overhanging sequence so that when integrated into the integrated nucleic acid, the multiple types of unit nucleic acids are aligned in a particular order and / or characteristic direction.
- one or more unit nucleic acids may be designed to encode one or more genes having a long base length.
- genes having a long base length include a group of genes constituting a series of metabolic pathways.
- a unit vector can be prepared by ligating a unit nucleic acid and an additional nucleic acid different from the unit nucleic acid. By using the unit vector, it may be possible to handle the unit nucleic acid more easily.
- the added nucleic acid may be a linear nucleic acid or a circular plasmid.
- the unit vector can also have a cyclic structure and can be used, for example, for transformation of Escherichia coli and the like.
- the added nucleic acid may include an origin of replication such that the unit vector is replicated in the introduced host.
- all unit nucleic acids for constructing an integrated nucleic acid may be linked to the same type of additional nucleic acid, thereby reducing the size difference between unit vectors and multiple types of units. The handling of the vector may be easier.
- the unit nucleic acid for constructing an integrated nucleic acid may be linked to different types of additional nucleic acids.
- the ratio of (base length of unit nucleic acid) / (base length of unit vector) or the average thereof is 50% or less, 40. % Or less, 30% or less, 20% or less, 15% or less, 10% or less, 7% or less, 5% or less, 2% or less, 1.5% or less, 1% or less or 0.5% or less.
- the larger the size of the added nucleic acid the more uniform handling of different types of unit vectors may be possible.
- the ligation between the unit nucleic acid and the added nucleic acid can be carried out by any method such as ligation using DNA ligase and TA cloning method.
- the ratio of (base length of unit nucleic acid) / (base length of unit vector) or the average thereof is 1% or more, 0. It can be 3% or higher, 0.1% or higher, 0.03% or higher, 0.01% or higher, 0.003% or higher, or 0.001% or higher, facilitating the manipulation of the unit vector.
- the length of the unit nucleic acid is 10 bp or more, 20 bp or more, 50 bp or more, 70 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 700 bp or more, 1000 bp or more or 1500 bp or more, and 5000 bp or less, 5000 bp or less, It can be 2000 bp or less, 1500 bp or less, 1200 bp or less, 1000 bp or less, 700 bp or less, or 500 bp or less.
- the accumulated nucleic acids are 2 or more, 4 or more, 6 or more, 8 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more or 100 or more, and 1000 or less, 700 or less, 500 or less, 200 or less, 120 or less, 100 or less, 80 or less, 70 It can be constructed from less than one species, no more than 60 species, no more than 70 species, or no more than 50 species of unit nucleic acid. By adjusting the number of moles of each unit nucleic acid (or unit vector) to be substantially the same, a desired integrated nucleic acid having a tandem repeat-like structure can be efficiently produced.
- the unit nucleic acid may have a base length obtained by dividing a set of repetitive sequences in the integrated nucleic acid into approximately equal parts by the number of unit nucleic acids. By doing so, the operation of aligning the number of moles of each unit nucleic acid (or unit vector) may be facilitated.
- the unit nucleic acid is 30% or less, 25% or less, 20% or less, 15% or less, 10% or less from the base length obtained by dividing a set of repetitive sequences in the integrated nucleic acid into approximately equal parts by the number of unit nucleic acids. , Can have an increased or decreased base length of 7% or less or 5% or less.
- the unit nucleic acid may be designed to have a non-palindromic sequence (a sequence that is not a parindrome sequence) at the end of the unit nucleic acid.
- a non-palindromic sequence a sequence that is not a parindrome sequence
- the unit nucleic acid designed in this way can easily give a structure in which the unit nucleic acids are linked in order with each other in the integrated nucleic acid.
- Accumulated nucleic acid can be constructed by linking unit nucleic acids to each other.
- the unit nucleic acid can be prepared by excising from a unit vector with a restriction enzyme or the like.
- the integrated nucleic acid may contain one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more or ten or more sets of repetitive sequences. .. Repeated sequences in the integrated nucleic acid may include the sequence of the unit nucleic acid and optionally the sequence of the integrated vector nucleic acid.
- the integrated nucleic acid may have a sequence that allows the nucleic acid to replicate in the transformed organism.
- the sequence that allows the replication of nucleic acid in the transformed organism may comprise an effective replication initiation site in the transformed organism (eg, Bacillus bacterium (Bacillus subtilis)).
- the sequence of the origin of replication effective in Bacillus subtilis is not particularly limited, but for example, pTB19 (Imanaka, T., et al. J.Gen.Microbioi. 130, 1399) has a ⁇ -type replication mechanism. -1408. (1984)), pLS32 (Tanaka, T and Ogra, M. FEBS Lett. 422, 243-246. (1998)), pAM ⁇ 1 (Swinfield, TJ, et al. Gene 87, 79-90. (1990). )) And the sequence of the origin of replication contained in the plasmid.
- the integrated nucleic acid may contain an additional base sequence, if necessary, in addition to the unit nucleic acid.
- the integrated nucleic acid may comprise a base sequence that controls transcriptional translation of a promoter, operator, activator, terminator, etc.
- a promoter when Bacillus subtilis is used as a host, Pspac (Yansura, D. and Henner, D.J. Pro. Natl. Acad. Sci, USA 81, whose expression can be controlled by IPTG (isopropyl s-D-thiogalactopyranoside) 439-443. (1984.)), or Pr promoter (Itaya, M. Biosci. Biotechnol. Biochem. 63, 602-604. (1999)) and the like.
- the unit nucleic acid can form a repeating structure in the integrated nucleic acid that maintains a certain order and orientation.
- the unit nucleic acid is constructed so that the base sequences of the protruding ends of the unit nucleic acid excised from the unit vector are complementary to each other, so that the repeating structure in the integrated nucleic acid is maintained in a certain order and orientation. Formation may be possible.
- the structure of the protruding end unique for each different unit nucleic acid, it is possible to efficiently form a repeating structure that maintains a constant order and orientation.
- the protruding end may have a non-palindromic sequence and may be either a 5'end overhang or a 3'end overhang.
- a restriction enzyme can be used to excise a unit nucleic acid having a protruding end from the unit vector.
- the unit vector may have one or more restriction enzyme recognition sequences.
- each restriction enzyme recognition sequence may be recognized by the same restriction enzyme or a different restriction enzyme.
- the unit vector may contain a pair of regions recognized by the same restriction enzyme such that the complete unit nucleic acid region is contained between these regions.
- restriction enzymes used are not particularly limited, but are limited to type II restriction enzymes such as AarI, BbsI, BbvI, BcoDI, BfuAI, BsaI, BsaXI, BsmAI, BsmBI, BsmFI, BspMI, BspQI, BtgZI, FokI, Sfa.
- Type IIS restriction enzymes can be used, and these restriction enzymes may be able to create protruding ends at a site some distance from the recognition sequence outside the recognition sequence.
- the unit vector does not include a region recognized by the type IIS restriction enzyme in the unit nucleic acid region.
- the unit vector may include a region recognized by the restriction enzyme at the end of the unit nucleic acid region.
- the restriction enzyme treatment can be performed in a solution containing the plurality of unit vectors, and the efficiency of work can be improved. Can be improved.
- the type of restriction enzyme used to prepare a certain integrated nucleic acid may be, for example, 5 or less, 4 or less, 3 or less, 2 or less, or 1 type, and by using a small number of restriction enzymes. , The variation in the number of moles between unit nucleic acids can be reduced.
- the unit nucleic acid excised from the unit vector can be easily purified by any known fractionation method such as agarose gel electrophoresis.
- the unit nucleic acid and, if necessary, the integrated vector nucleic acid can be ligated to each other using DNA ligase or the like. This makes it possible to prepare an integrated nucleic acid.
- the linkage of the unit nucleic acid and optionally the integrated vector nucleic acid is the presence of components such as polyethylene glycol (eg, PEG2000, PEG4000, PEG6000, PEG8000, etc.) and salts (eg, monovalent alkali metals, sodium chloride, etc.). Can be carried out below.
- the concentration of each unit nucleic acid in the ligation reaction solution is not particularly limited and may be 1 fmol / ⁇ l or more.
- the reaction temperature and time of the ligation are not particularly limited, such as 30 minutes or more at 37 ° C.
- the composition comprising the unit nucleic acid and optionally the integrated vector nucleic acid may be subjected to any condition to inactivate the restriction enzyme prior to ligation of the unit nucleic acid and optionally the integrated vector nucleic acid. Good (eg, phenol / chloroform treatment).
- the unit nucleic acid can be adjusted to substantially the same number of moles by using the method described in WO2015 / 11248. By adjusting the unit nucleic acid to approximately the same number of moles, a desired integrated nucleic acid having a tandem repeat-like structure can be efficiently produced.
- the number of moles of unit nucleic acid can be adjusted by measuring the concentration of unit vector or unit nucleic acid.
- the transforming organism includes a bacterium belonging to the genus Bacillus, a bacterium belonging to the genus Streptococcus, a bacterium belonging to the genus Haemophilus, a genus Neisseria and the like.
- Bacteria of the genus Bacillus include B. Subtilis (Bacillus subtilis), B.I. Megaterium (giant ground sloth), B. Examples include stearothermophilus (moderate thermophile).
- the transformant is Bacillus subtilis.
- the transformant that uptakes the accumulated nucleic acid is in a competent state and can actively uptake the nucleic acid.
- Bacillus subtilis in a competent state cleaves a double-stranded nucleic acid as a substrate on a cell, decomposes one of the double-stranded nucleic acids from this cleavage point, and decomposes the other single-stranded nucleic acid. Incorporate into the cells. The incorporated single-stranded nucleic acid can be repaired to a circular double-stranded nucleic acid in the cells.
- Any known method can be used to bring the transformant into a competent state, for example Bacillus subtilis is described in Anagnostopoulou, C. and Spizizen, J. J. Bacteriol., 81, 741-746 (1961). It can be made competent using the method.
- the transformation method a known method suitable for each transformed organism can be used.
- vector plasmids produced from packaging cells can be purified using any known method, and the present disclosure also provides vector plasmids thus purified. In one embodiment, it can be confirmed that the purified vector plasmid has a desired nucleic acid sequence by examining the size pattern of the fragment generated by restriction enzyme cleavage, PCR method, nucleotide sequence determination method, or the like. In one embodiment, the vector plasmid-containing composition prepared by the vector plasmid preparation method of the present disclosure may contain a small amount of endotoxin. In one embodiment, Bacillus subtilis comprising the vector plasmid of the present disclosure is provided.
- composition comprising a vector plasmid or viral vector described herein.
- compositions described herein can be provided in various forms.
- the form of the composition may be, for example, an injection, a capsule, a tablet, a granule, an inhaler or the like.
- the aqueous solution for injection may be stored, for example, in a vial or a stainless steel container. Further, the aqueous solution for injection may contain, for example, physiological saline, sugar (for example, trehalose), NaCl, NaOH or the like.
- the composition of the present disclosure comprises a pharmaceutically acceptable carrier or excipient.
- a pharmaceutically acceptable carrier or excipient can also be sterile liquids such as water and oil, including, but not limited to, petroleum, animal, plant or synthetic origins, sesame oil, soybean oil, minerals. Includes oil, sesame oil, etc. Water is the preferred carrier for oral administration of the drug.
- saline and aqueous dextrose are the preferred carriers.
- aqueous saline solution, as well as aqueous dextrose and glycerol solutions are used as liquid carriers for injectable solutions.
- Suitable excipients include light anhydrous silicic acid, crystalline cellulose, mannitol, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, choke, silica gel, sodium stearate, glycerol monostearate, talc, chloride.
- composition contains 60 castor oil, poroxamar, sucrose, carboxymethyl cellulose, corn starch, inorganic salts and the like.
- the composition can also contain small amounts of wetting or emulsifying agents, or pH buffers, if desired.
- compositions can also take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations and the like. It is also possible to formulate the composition as a suppository using traditional binders and carriers such as triglycerides. Oral formulations can also include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate and the like. Examples of suitable carriers are described in E.W.Martin, Remington's Pharmaceutical Sciences (Mark Publishing Company, Easton, U.S.A.).
- any liquid composition of the present disclosure is about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, It can be in the range of about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11 or any two of these.
- compositions of the present disclosure can be provided as a pharmaceutically acceptable salt and is formed with a free carboxyl group derived from, for example, hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartrate acid and the like.
- Salts, salts formed with free amine groups such as those derived from isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, prokine, etc., as well as sodium, potassium, ammonium, calcium, and ferric hydroxide. It can be a salt formed with.
- the composition can be formulated as a pharmaceutical composition adapted for administration to humans according to a known method.
- Such compositions can be administered by injection.
- the composition for injection administration is a solution in a sterile isotonic aqueous buffer.
- the composition can also contain a solubilizer and a local anesthetic such as lidocaine to relieve pain at the injection site.
- the ingredients are supplied separately or mixed together in a unit dosage form and fed, for example in a sealed container such as an ampoule or sachet indicating the amount of activator, lyophilized powder or water-free concentrate. It can be supplied as a thing.
- composition is to be administered by infusion, it can also be dispensed using an infusion bottle containing sterile drug grade water or saline. If the composition is to be administered by injection, it is also possible to provide an ampoule of sterile water or saline for injection so that the ingredients can be mixed prior to administration.
- the vector plasmids or viral vectors described herein, or compositions containing them, can be used in a variety of applications such as gene therapy, functional genomics, cancer vaccination and / or antiviral vaccination.
- the subject is not particularly limited, and the subject is not particularly limited to mammals (for example, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, pigs, etc. Can be monkeys, humans, etc.), birds, reptiles, amphibians, limbs, fish, etc.
- mammals for example, mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, pigs, etc.
- birds reptiles, amphibians, limbs, fish, etc.
- the amount of viral vector or viral vector-containing composition disclosed herein may vary depending on the nature of the disorder or condition being treated or prevented, but one of ordinary skill in the art can be determined by standard clinical techniques as described herein. In some cases, in vitro assays can be used to help identify the optimal dosage range.
- the exact dose to be used in the formulation may also vary depending on the route of administration and the severity of the disease or disorder and should be determined according to the judgment of the attending physician and the circumstances of each patient.
- the dose of the viral vector or the composition containing the viral vector of the present disclosure is not particularly limited, but for example, 1 ⁇ 10 5 pieces, 1 ⁇ 10 6 pieces, 1 ⁇ 10 7 pieces, 1 ⁇ 10 8 pieces, 1 ⁇ 10 at a time.
- the number of viral vectors may be ⁇ 10 9 , 1 ⁇ 10 10 , 1 ⁇ 10 11 , 1 ⁇ 10 12 , 1 ⁇ 10 13 , 1 ⁇ 10 14 or 1 ⁇ 10 15 . , It may be within the range of any two of them.
- the dosing interval is not particularly limited, but may be administered once or twice per 1, 7, 14, 21, or 28 days, for example, once or twice per range of any two values. May be good.
- the dose, administration interval, and administration method may be appropriately selected depending on the age and weight of the patient, symptoms, target organ, and the like.
- the routes of administration of the viral vector or the viral vector-containing composition described herein are, for example, intravenous, intradermal, subcutaneous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrabrain parenchyma, transpulmonary, nasal. It may be administered internally, epidurally, orally.
- the compositions of the present disclosure various delivery systems, can be used together. Such systems include, for example, the use of liposomes, microparticles, and inclusions in microcapsules: receptor-mediated endocytosis.
- Inhalers or atomizers can be used with the aerosolating agent, and can be administered with other agents. Administration can also be systemic or topical.
- the composition of the present disclosure can be provided as a kit.
- the disclosure is a kit for making a vector plasmid, comprising at least one nucleic acid sequence that promotes plasmid replication in bacillus and a nucleic acid sequence required to construct a virus.
- a kit containing one nucleic acid is provided.
- the disclosure provides a drug pack or kit comprising one or more containers filled with one or more components that can be added to the compositions of the present disclosure.
- composition of the present disclosure as a pharmaceutical product is known in the art, and is described in, for example, the Japanese Pharmacopoeia, the United States Pharmacopeia, the Pharmacopoeia of other countries, and the like. Therefore, a person skilled in the art can determine an embodiment such as an amount to be used without conducting an excessive experiment, if the description of this specification is given.
- AAV vector plasmid amplification AAV vector plasmids were prepared according to the following procedure and amplified with Escherichia coli and Bacillus subtilis.
- the plasmids of pAAV-CMV vector, pRC2-mi342 vector, and pHelper vector were purchased from Takara Bio (Shiga Prefecture).
- the Bacillus subtilis-E. coli shuttle plasmid vector, pGETS103 ⁇ AarI is a plasmid pGETS103 (Tsuge, K., Itaya, M. (2001) Recombinational transfer of 100-kilobase genomic DNA to plasmid in Bacillus subtilis 168, Journal of Bacteriology, 183, 5453.
- the chemical competent cell of Escherichia coli JM109 strain was purchased from Takara Bio.
- Bacillus subtilis BUSY9797 strain (Tsuge, K., Sato, Y., Kobayashi, Y., Gondo, M., Hasebe, M., Togashi, T., Tomita, M., Itaya, M.
- the TA cloning vector pMD19-Tv-vector and DNA Ligation Kit ⁇ Mighty Mix> were purchased from Takara Bio.
- the restriction enzyme AarI was purchased from Thermo Fisher Scientific (USA). All other restriction enzymes were purchased from New England Biolab (USA).
- TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) was purchased from Nacalai Tesque (Kyoto).
- Carbenicillin and tetracycline were purchased from Sigma-Aldrich (USA).
- 2-Hydroxyethyl agarose (Sigma-Aldrich) was used as the low melting point agarose.
- Invitrogen (USA) UltraPure Agarose was used.
- Phenol saturated TE was purchased from Nacalai Tesque.
- the QIA quick miniprep kit from Qiagen (Germany) and the PCR preparation kit were used as the column purification kit for the plasmid.
- Bactoryptone, Yeast extract and Bacto Agar were purchased from Becton Dickinson (USA).
- Other media reagents were purchased from Nacalai Tesque.
- the egg white lysozyme, ethidium bromide was purchased from Sigma-Aldrich.
- Ribonuclease A was purchased from Nacalai Tesque.
- P1, P2, and P3 used for plasmid purification were purchased from Qiagen.
- Cesium chloride was purchased from Nacalai Tesque.
- LB medium 10 g of Bactoryptone, 5 g of Yeast extract, and 5 g of sodium chloride were dissolved in 1 L of water, and when forming an agar plate, 15 g of Bacto Agar was further added and autoclaved (121 ° C., 20 minutes). used. If necessary, carbenicillin (final concentration 100 ⁇ g / ml) or tetracycline (final concentration 10 ⁇ g / ml) was added.
- the TF-1 medium and TF-II medium for Bacillus subtilis transformation were prepared as follows.
- TF-II medium The preparation of 500 ml of TF-II medium was the same as that of TF-I medium except that 2.5 ml of 2% casamino acid, 0.5 ml of each amino acid solution (5 mg / ml), and 435.5 ml of sterile water were used. The amount was added, filtered through a filter, and stored at 4 ° C. until use.
- DNA fragments are 0.7% low melting point agarose gel (2-Hydroxythyl Agarose Type VII, Sigma Aldrich), 1 x TAE buffer (Tris-Actate-EDTA Buffer,). In the presence of Nakaraitesk), a voltage of 100 V (about 8 V / cm) is applied and electrophoresed for 1 hour on a general-purpose agarose gel electrophoresis device (i-MyRun.N nucleic acid electrophoresis system, Cosmobio (Tokyo)). Thereby, the vector plasmid and the unit DNA were separated.
- i-MyRun.N nucleic acid electrophoresis system i-MyRun.N nucleic acid electrophoresis system, Cosmobio (Tokyo)
- This migration gel was stained with 100 ml of 1 ⁇ TAE buffer containing 1 ⁇ g / ml ethidium bromide for 30 minutes, and irradiated with long-wavelength ultraviolet light (366 mn) for visualization to cut out a PCR product of the desired size with a razor. Collected in 1.5 ml tubes. The gel was dissolved by adding 1 ⁇ TAE buffer to the recovered low melting point agarose gel (about 300 mg) to make the total volume about 700 ⁇ l, and incubating this at 65 ° C. for 10 minutes. Then, an equal amount of TE saturated phenol was added and mixed well to inactivate the restriction enzyme.
- the phenol phase and the aqueous phase were separated by centrifugation (20,000 ⁇ g, 10 minutes), and the aqueous phase (about 900 ⁇ l) was collected in a new 1.5 ml tube.
- the volume of the aqueous phase is 450 ⁇ l. By repeating until the following, the volume of the aqueous phase was reduced.
- Recombinant plasmid construction Required fragments (1.8 kb from pAAV-CMV) obtained from pAAV-CMV plasmid (Fig. 1), pRC2-mi342 plasmid (Fig. 2), pHelper plasmid (Fig. 3) by excision with restriction enzymes, etc.
- a recombinant plasmid was constructed by ligating a SbfI fragment, a 5.2 kb EagI-XmaI fragment from pRC2-mi342, and a 9.3 kb BamHI-BamHI-NdeI fragment from pHelper) into a plasmid for integration.
- the BamHI site is present in the VA region in the pHelper, the 0.3 kb fragment from this BamHI site to the nearby NdeI site was amplified and obtained by PCR. This fragment was amplified using primers introduced with the SbfI site, AarI site, and EagI-XmaI site so that the above three fragments could be introduced to obtain a PCR product having the sequence shown in SEQ ID NO: 1. Obtained.
- This PCR product was cloned into plasmid pMD19, and after confirming that the base sequence was correct, it was cleaved with BsaI designed near the end of the above DNA to obtain a fragment. This fragment was ligated to a fragment obtained by cleaving and dephosphorylating pGETS103 ⁇ AarI with HindIII. The resulting plasmid was named pGETS103-VA (FIG. 4).
- plasmid pRC2-mi342 was cleaved with EagI and XmaI, and large fragments of 5.2 kb were excised from the gel and purified, and these were ligated.
- the resulting plasmid was named pGETS103-RC2 (Fig. 5).
- a fragment of 1.8 kb obtained by cleaving the plasmid pAAV-CMV with SbfI into a fragment obtained by cleaving pGETS103-RC2 with SbfI and then performing phenol treatment and ethanol precipitation for restriction enzyme inactivation.
- the resulting plasmid was named pGETS103-AAV-RC2 (Fig. 6). Further, this is cleaved with AarI to remove a short DNA fragment, and a 9.0 kb BamHI fragment of the plasmid pHelper is ligated therein, and the BamHI is ligated in the direction in which the VA region is regenerated by the ligation with the previously introduced BamHI-NdeI region.
- pGETS103-AAV-Helper-RC2 having an all-in-one structure in which three plasmids were integrated into one plasmid was constructed (FIG. 7, SEQ ID NO: 2). Furthermore, a plasmid having the fragment alone was constructed.
- the plasmid obtained by ligating the 1.8 kb fragment obtained by cleaving the plasmid pAAV-CMV with SbfI to the pGETS103-VA cleaved with SbfI was named pGETS103-AAV (Fig.). 8).
- pGETS103-VA is cleaved with AarI to remove a short DNA fragment, and a 9.0 kb BamHI fragment of plasmid pHelper is ligated therein, and the VA region is regenerated by ligation with the previously introduced BamHI-NdeI region.
- the pGETS103-Helper was constructed by selecting the one in which the BamHI fragment was introduced in the direction (Fig. 9).
- Escherichia coli transformation method Transfer 50 ⁇ l of lysed Escherichia coli JM109 competent cells to a 1.5 ml centrifuge tube prepared on ice, add recombinant plasmid to a maximum of 5 ⁇ l, and allow to stand on ice for 15 minutes. After incubating for 45 seconds in a warm bath at 42 ° C., returning to ice and 2 minutes later, add 200 ⁇ l of the SOC medium attached to the competent cells, and add 200 ⁇ l of the SOC medium attached to the competent cell to the rotary culture device (RT-50 with the culture holder SA-1811 for a test tube). It was set in Tytech (Osaka)) and cultured at 37 ° C. for 1 hour at a rotation speed of 30 rpm. Then, this was smeared on an LB medium agar plate containing carbenicillin, and cultured at 37 ° C. overnight.
- Tytech Osaka
- Bacillus subtilis transformation method Put 2 ml of LB medium in a 14 ml test tube (2051) of Falcon (registered trademark), inoculate Bacillus subtilis of glycerol stock stored at ⁇ 70 ° C., and rotate in a rotary culture device. , 37 ° C. for 17 hours. 900 ⁇ l of TF-I medium was dispensed into a new 14 ml test tube (Falcon 2051), 25 ⁇ l of 2% casamino acid was added, 50 ⁇ l of the above culture solution was added, and 4 at 37 ° C. while rotating in a rotary incubator. Incubated for hours.
- 900 ⁇ l of TF-II medium was dispensed into a new 14 ml test tube, 100 ⁇ l of TF-I culture solution was added, and the cells were cultured at 37 ° C. for 1.5 hours while rotating in a rotary incubator.
- 100 ⁇ l of TF-II culture medium was placed in a 1.5 ml centrifuge tube, and 8 ⁇ l of recombinant plasmid was added.
- 300 ⁇ l of LB medium was added, and the cells were further cultured at 37 ° C. for 1 hour while rotating in a rotary culture device.
- the culture was spread on an LB medium agar plate containing 10 ⁇ g / ml of tetracycline and incubated overnight at 37 ° C. to obtain a transformant.
- Mass preparation method of plasmid from Bacillus subtilis and Escherichia coli High-purity plasmid DNA was procured by cesium chloride-ethidium bromide density gradient ultracentrifugation method. The following shows the purification method in the case of 200 ml of LB medium, but when it exceeds 200 ml, the following operation was repeated every 200 ml. 200 ml of LB medium to which an antibiotic (tetracycline) was added was prepared, 100 ml each was placed in a 500 mlenmeyer flask, inoculated with an Escherichia coli or Bacillus subtilis plasmid-carrying strain, and cultured at 37 ° C. overnight.
- the weight was finely adjusted by adding water or a 1.1 g / ml cesium chloride solution (specific gravity of about 1.5 g / ml) so that the difference in weight from the balance was within 20 mg. Centrifugation was performed under the following conditions with an ultracentrifuge (Beckman Coulter). Temperature: 18 ° C., Velocity: 50,000 rpm, Acceleration: Max, Deceleration: Max. Centrifuged for 15 hours or more.
- a 600 ⁇ l PB mixture was applied to the Kit spin column and centrifuged at 20,000 ⁇ g for 1 minute. The flow-through was discarded and the remaining 600 ⁇ l PB mixture was reapplied to the above column and 20,000 ⁇ g. Centrifuge for 1 minute with. Discard the flow-through, set the column in the collection tube again, apply 700 ⁇ l of PE and centrifuge at 20,000 xg for 1 minute (1st time). Discard the flow-through again and column. Was set in the collection tube again, 700 ⁇ l of PE was applied, and the mixture was centrifuged at 20,000 ⁇ g for 1 minute (second time). Apply and centrifuge at 20,000 xg for 1 minute (3rd time).
- Example 2 Production of AAV vector from amplified vector plasmid
- Vector plasmids amplified with E. coli and Bacillus subtilis were introduced into producer cells to produce AAV vectors.
- the experiments in this example were commissioned by SignaGen Laboratories (USA).
- the prepared DNA complex was transfected into cultured 2x108 cells of HEK293 cells ( passage number 12), and the culture was continued for another 5 hours. Transfected cells were harvested, thawed three times, and then treated with Benzonaze® at 37 ° C. for 1 hour. Centrifugation was performed at 12500 rpm for 30 minutes, and the supernatant was collected. Next, after performing cesium chloride density gradient ultracentrifugation at 28000 rpm for 18 hours, rAAV (recombinant adeno-associated virus vector particles) was recovered and dispersed in PBS containing 0.001% Pluronic® F-68. rice field.
- rAAV recombinant adeno-associated virus vector particles
- the prepared genome copy titer of rAAV was quantified using quantitative PCR. After each rAAV was treated with DNase I, proteinase K was used to inactivate DNase I. The capsid was denatured by heat treatment at 98 ° C. for 15 minutes, diluted so as to be within the range of the calibration curve, and then measured by quantitative PCR. The target was ITR, and primers of the sequences of 5'-GGAACCCTAGTGAGGAGTT-3'(SEQ ID NO: 67) and 5'-CGGCTCCAGTGAGCGA-3' (SEQ ID NO: 68) were used. In addition, the amount of endotoxin contained in the rAAV dispersion was quantified using the Pierce LAL Endotoxin Quantionation Kit (Thermo Fisher Scientific, USA).
- the amount of rAAV virus genome [VG / mL] and the amount of endotoxin [Unit / mL] produced under each plasmid condition were measured. Production of rAAV virus was similarly confirmed under all conditions. No endotoxin was detected under any of the conditions.
- Example 3 CCC purity of the constructed plasmid DNA
- the CCC (covalently closed circular) purity of the plasmid DNA used to prepare rAAV was quantified using P / ACE MDQ Plus (SCIEX) and dsDNA 1000 kit (AB SCIEX, Tokyo). 20 mL of ultrapure water was added to the gel powder included in the kit, and the mixture was stirred overnight. After confirming that the gel was completely dissolved, it was diluted 10-fold with 1xTBE electrophoresis buffer (Thermovisher). After adding SYBR Gold nucleic acid gel stain (Thermovisher) to the diluted gel so as to be 0.01 vol%, the capillary was filled with the gel. Each plasmid DNA was adjusted to 10 ng / ⁇ L with ultrapure water and measured using P / ACE MDQ Plus.
- the CCC purity was higher in Bacillus subtilis than in E. coli.
- the plasmids of the present disclosure may have high CCC purity. According to the FDA guidance, the CCC purity is specified to be higher than 80%, but since it was observed that the plasmid produced using Bacillus subtilis has a high CCC purity, a purification operation for improving the CCC purity was performed. The burden and manufacturing cost can be reduced. CCC purity is also considered to be related to the stability, functionality, and transfection efficiency of plasmid DNA, and plasmid DNA with high CCC purity is highly useful.
- the PCR conditions were as follows: after heating at 95 ° C. for 15 minutes, a cycle of (1) 94 ° C. for 15 seconds, (2) 60 ° C. for 30 seconds, and (3) 72 ° C. for 30 seconds was repeated 40 times.
- a calibration curve was prepared using DNA linearized with pAAV-CMV with a restriction enzyme, and the rAAV genome copy concentration was calculated from each Ct value. The proportion of rAAV containing the complete genome was calculated by dividing the genome copy concentration calculated with CMV as the target by the number of genome copies calculated with ITR as the target.
- the proportion of complete genome was particularly high in rAAV # 1 (all-in-one, Bacillus subtilis) and rAAV # 3 (all-in-one, Escherichia coli). Since the genome contains nucleic acid in the virus particle, it is difficult to separate the complete genome-containing virus particle and the incomplete genome-containing virus particle after the virus vector preparation, and a virus containing the complete genome in a high proportion at the virus vector preparation stage. It is highly desirable to be able to prepare the particles.
- the plasmids of the present disclosure may provide a viral vector containing the complete genome with high efficiency.
- Example 5 Ratio of rAAV containing a marker gene
- Each rAAV cryopreserved in SignaGen was thawed and quantitative PCR was performed on the Ampr gene contained in the plasmid backbone using Step One plus.
- a TE buffer was added to the prepared rAAV, diluted 3-fold, and then heated at 95 ° C. for 10 minutes using a thermal cycler for PCR, and the extracted rAAV genome was used as a template for quantitative PCR.
- the reaction solution for quantitative PCR is Quantitect SYBR Green PCR Master mix 10 ⁇ L, 0.01 mM primer (forward: 5'-TTGATCGTTGGAACCGGAG-3'(SEQ ID NO: 71)) 1 ⁇ L, 0.01 mM primer (reverse: 5'-TTGTTGCCGGGAAGCTAGAG-3'(SEQ ID NO: 72)) 1 ⁇ L, water 6 ⁇ L, template 2 ⁇ L was included, the plate was sealed with a seal, and then PCR was performed.
- the PCR conditions were as follows: after heating at 95 ° C. for 15 minutes, a cycle of (1) 94 ° C. for 15 seconds, (2) 60 ° C. for 30 seconds, and (3) 72 ° C. for 30 seconds was repeated 40 times.
- a calibration curve was prepared using DNA obtained by linearizing pAAV-CMV with a restriction enzyme, and the genome copy concentration was calculated from each Ct value.
- the proportion of rAAV containing the marker gene was calculated by dividing the genome copy concentration calculated with Ampr as the target by the number of rAAV genome copies calculated with CMV as the target.
- the proportion of impurities was particularly low in rAAV # 1 (all-in-one, Bacillus subtilis) and rAAV # 4 (three-kind mixed plasmid, Escherichia coli). It was suggested that the combination of the plasmid with the all-in-one structure and Bacillus subtilis was excellent.
- Example 6 Ratio of empty capsid
- Each rAAV cryopreserved in SignaGen was thawed, and the capsid particle concentration was quantified by the ELISA method using ARVO X5 (PerkinElmer).
- AAV2 Titration ELISA 2.0R PROGEN was used as the quantification kit, and the test was conducted based on the protocol. 100 ⁇ L each of rAAV and a standard product (empty capsid reagent included in the kit) was added to a 96-well plate on which the anti-AAV2 antibody included in the kit was immobilized. After allowing to stand at 37 ° C. for 1 hour, the solution was discarded and washed 3 times with 200 ⁇ L of assay buffer.
- the ratio of empty capsids is obtained by subtracting the value obtained by dividing the rAAV genome copy concentration (genome copy titer) calculated by targeting CMV by the capsid particle concentration (virus particle titer) quantified by the ELIZA method from 1. Calculated.
- the proportion of empty capsids was particularly low in rAAV # 1 (all-in-one, Bacillus subtilis). Empty capsids can be immunogenic and are preferably reduced. As described in Example 2, cesium chloride density gradient ultracentrifugation was performed during the acquisition of rAAV, and although it is possible that this operation partially removed the empty capsid, the empty capsid is essentially empty. It is considered that it has not been removed. Efficient removal of empty capsids is usually difficult even with column chromatography, so it is particularly preferred to reduce the formation of empty capsids in the upstream process. However, in the viral vector prepared by the method of the present disclosure, the proportion of empty capsid is particularly low, and it is possible to produce a highly efficient viral vector. Therefore, the burden of the empty capsid removal operation, which may require labor such as a separation method based on a slight difference in density, can be reduced.
- the plasmid pGETS103 ⁇ AarI was cleaved with the restriction enzyme HindIII, purified by TE saturated phenol treatment, butanol extraction, and ethanol precipitation, and the single-stranded DNA represented by SEQ ID NOs: 3 and 4 was annealed to this to prepare it.
- the linker DNA was inserted to prepare pGETS103- ⁇ AarI-Linker, which is a vector for OGAB accumulation.
- This plasmid was cleaved with the restriction enzyme AarI, size-separated by low melting point agarose gel electrophoresis, and a large 15 kb fragment was excised from the gel and purified to obtain a vector fragment for OGAB accumulation.
- MAP using single-stranded DNA of SEQ ID NOs: 5 to 10 for the first fragment, SEQ ID NOs: 11 to 16 for the third fragment, and SEQ ID NOs: 17 to 22 for the 16th fragment.
- Double-stranded DNA obtained by assembling by the method was used.
- the combination of the numbered F and R primers of each fragment shown in SEQ ID NOs: 23 to 66 was used, the pAAV-CMV Vector for the second fragment, and the pHelper Vector for the fourth to fifteenth fragments.
- the 17th to 22nd fragments were amplified by PCR under the following conditions using pRC2-mi342 Vector as a template.
- the obtained DNA solution was measured using a microspectrophotometer (Nano drop One, Thermo Fisher), and TE buffer was added to dilute it to 100 ng / ⁇ l. After that, the concentration is measured again, the DNA volume required to accurately separate 500 ng of DNA is calculated to 2 digits after the decimal point ⁇ l, and the equimolar distribution of each plasmid is performed by distributing with a micropipette. gone.
- the separated DNA solution was divided into two 1.5 ml centrifuge tubes and pooled according to the type of restriction enzyme used thereafter.
- the plasmid for cloning the 1st, 3rd, 5th, 7th, 9th, 11th, 13th, 14th, 17th, 19th, and 21st fragments is put into a tube to be cleaved with the restriction enzyme AarI, and the 2nd, 4th, 6th, 8th, 10th, and so on.
- the plasmids that clone the 12, 15, 16, 18, 20, and 22 fragments were pooled in groups that were cleaved with the restriction enzyme BsaI, respectively.
- TE buffer was added to 1 fmol of the obtained DNA solution and 1 fmol of pGETS103 ⁇ AarI-Linker cleaved and purified with AarI so as to have a total of 4 ⁇ l.
- 2 ⁇ ligation buffer (15% polyethylene glycol 6000, 500 mM NaCl, 132 mM Tris ⁇ HCl (pH 7.6), 13.2 mM MgCl 2 , 20 mM DTT, 0.2 mM ATP
- T4 DNA ligase (Takarabio) was added and incubated at 37 ° C. for 5 hours. 100 ⁇ l of Bacillus subtilis competent cells was added thereto, and the cells were cultivated by rotation with a duck rotor at 37 ° C. for 30 minutes. Then, 300 ⁇ l of LB medium was added and cultivated in a duck rotor at 37 ° C. for 1 hour, and then the culture broth was spread on an LB plate containing 10 ⁇ g / ml tetracycline (Sigma-Aldrich) and cultured at 37 ° C. overnight. .. 94 colonies were obtained.
- the obtained bacterial cell pellet was well suspended, 100 ⁇ l of P1 buffer containing 10 mg / ml egg white lysozyme (wako) was added, and the mixture was incubated at 37 ° C. for 5 minutes. 200 ⁇ l of P2 buffer was added thereto, and the mixture was allowed to mix four times. Then, 150 ⁇ l of P3 was added and mixed by quadrupling. This was centrifuged at 20,000 ⁇ g for 10 minutes to separate into a white precipitate and a supernatant.
- Example 8 Construction of various AAV all-in-one vector plasmids
- seven vector plasmids with an all-in-one structure for producing AAV viral vectors were constructed using components obtained from the AAV and adenovirus genomes of other serum types.
- pGETS118-AarI Tsuge, K., Sato, Y., Kobayashi, Y., Gondo, M., Hasebe, M., Togashi, T., Tomita, M., and Itaya, M. Method of preparing an equimolar DNA
- Each plasmid was constructed based on the mixture for one-step DNA assembly of over 50 fragments. Sci Rep 5, 10655 (2015). (Schematic diagram is shown in FIG. 16).
- the serotypes of the viral genomes from which ITR, Rep, Cap and Helper (VA, E2A and E4) used in each of the vector plasmids are shown in the table below (see also Figure 17).
- the vector plasmid of * 1 is that of the above-mentioned example (pGETS103-AAV-Helper-RC2).
- AAV Adeno-associated virus serotype
- Ad Adenovirus serotype and group
- each of the above all-in-one nucleic acids (total length 15 to 16 kb) was designed, and DNA fragments containing 18 to 19 unit DNA fragments (700 to 900 bp) were chemically synthesized according to the length. These DNA fragments were excised with any of AarI, BbsI, BsaI, and BsmBI restriction enzymes to prepare unit DNA fragments. These unit DNA fragments were tandemly ligated with pGETS118 cleaved with AarI, and then a circular plasmid was formed in Bacillus subtilis by the OGAB method as in the above example. As a result, the construction of the above-mentioned additional seven types of AAV all-in-one structure vector plasmids was confirmed.
- each viral vector was produced by introducing these plasmids into cultured cells (producer cells) (Fig. 18).
- Example 9 Construction of adenovirus all-in-one vector plasmid
- Ad5 adenovirus vector Ad5
- Ad5 adenovirus vector Ad5
- AarI, BbsI, BsaI, and BsmBI restriction enzymes were excised with any of AarI, BbsI, BsaI, and BsmBI restriction enzymes to prepare unit DNA fragments.
- FIG. 21 is a construction example using Rep of AAV1 and Cap of AAV6 based on pGETS103- ⁇ AarI.
- FIG. 22 is a construction example using the CAG promoter based on pGETS103- ⁇ AarI, Rep of AAV5 and Cap of AAV1.
- FIG. 23 is an example of construction using the EF1 ⁇ promoter based on pGETS103- ⁇ AarI, Rep of AAV8 and Cap of AAV9.
- FIG. 21 is a construction example using Rep of AAV1 and Cap of AAV6 based on pGETS103- ⁇ AarI.
- FIG. 22 is a construction example using the CAG promoter based on pGETS103- ⁇ AarI, Rep of AAV5 and Cap of AAV1.
- FIG. 23 is an example of construction using the EF1 ⁇ promoter based on pGETS103- ⁇ AarI, Rep of AAV8 and Cap of AAV9.
- FIG. 21 is a construction example using Rep of AAV1
- FIG. 24 is a construction example in which the SV40 promoter based on pGETS103- ⁇ AarI is used and Rep, Cap and Helper are arranged in different orders.
- FIG. 25 is a construction example in which Rep, Cap and Helper based on pGETS131-AarI are arranged in different orders.
- FIG. 26 is a construction example in which the element of the Helper gene based on pBETS103- ⁇ AarI is modified (separated from other elements and adenoviruses E1A and E1B are added).
- Example 11 Construction of viral vector plasmids based on various viruses
- the AAV viral vector plasmid should further contain the E1A and E1B genes in addition to the structures of the above examples. Can be built.
- FIGS. 12 to 15 are assumed based on pGETS103 ⁇ AarI of the above example.
- Lentiviral vector plasmid (Fig. 12) The following nucleic acid sequences are added based on pGETS103 ⁇ AarI to construct a vector plasmid.
- ⁇ CMV promoter VSV-G (glycoprotein G of vesicular stomatitis virus), poly A ⁇ CMV promoter, rev, poly A ⁇ 5'LTR, ⁇ (packaging signal sequence), RPE, PPT, CMV promoter, WPRE, 3'LTR -CMV promoter, gag, pol, RPE, poly A (The desired gene can be located downstream of the promoter between the LTRs.)
- Retroviral vector plasmid (Fig. 13) The following nucleic acid sequences are added based on pGETS103 ⁇ AarI to construct a vector plasmid. ⁇ CMV promoter, env, poly A ⁇ 5'LTR, ⁇ (packaging signal sequence), RPE, PPT, CMV promoter, WPRE, 3'LTR -CMV promoter, gag, pol, RPE, poly A (The desired gene can be located downstream of the promoter between the LTRs.)
- Sendai virus vector plasmid (Fig. 14) The following nucleic acid sequences are added based on pGETS103 ⁇ AarI to construct a vector plasmid.
- ⁇ CAG promoter, T7 RNA polymerase ⁇ CAG promoter, N ⁇ CAG promoter, P, L, F -T7 promoter, F-deficient Sendai virus genome, Rbz (The desired gene can be located between any gene in the Sendai virus genome.)
- Adenovirus vector plasmid (Fig. 15) The following nucleic acid sequences are added based on pGETS103 ⁇ AarI to construct a vector plasmid. 5'ITR, adenovirus serotype 5 genome (replace the site of the E1 gene with a promoter and the E1A gene), 3'ITR (In addition to the E1A gene, the desired gene can also be located downstream of the above or other promoters.)
- Coronavirus vector plasmid (Fig. 27) A coronavirus vector plasmid is constructed by adding the following nucleic acid sequences based on pGETS103 ⁇ AarI. -Contains ORF1a in the nonstructural protein region, ORF1b in the nonstructural protein region, and the structural protein region, and contains the desired gene in the structural protein region. The spike gene S, envelope gene E, matrix gene M, nucleocapsid gene N, etc. in the structural protein region may be deleted if necessary.
- the present disclosure may provide a vector plasmid with a novel structure and enable the supply of a viral vector based on the vector plasmid.
- SEQ ID NO: 1 PCR product tagGGTCTCaAGCTtgCCTGCAGGcaGATCatgcgcaggtgcacctgcatgcGATCCGGGGTTCGAACCCCGGTCGTCCGCCATGATACCCTTGCGAATTTATCCACCAGACCACGGAAGAGTGCCCGCTTACAGGCTCTCCTTTTGCACGGTCTAGAGCGTCAACGACTGCGCACGCCTCACCGGCCAGAGCGTCCCGACCATGGAGCACTTTTTGCCGCTGCGCAACATCTGGAACCGCGTCCGCGACTTTCCGCGCCTCCACCACCGCCGCCGGCATCACCTGGATGTCCAGGTACATCTACGGATTACGTCGACGTTTAAACCATATGAGCGGCCGCatatatCCCGGGAGCTaGAGACCtca SEQ ID NO: 2: pGETS103-AAV-Helper-RC2 (As described in the sequence sheet) SEQ ID NO: 3: Linker F AGCTTGCAGGTGCACCTGCATGCGG SEQ ID NO: 4: Linker F
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(項目A1)
枯草菌においてプラスミド複製を促進する核酸配列と、
ウイルスベクターを構成するのに必要な核酸配列のうちの少なくとも1つと、
を含むプラスミド。
(項目A2)
前記ウイルスベクターを構成するのに必要な核酸配列は、
前記ウイルスのカプシドタンパク質をコードする核酸配列と、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列と、
前記ウイルスの2つの末端反復配列と、
ヘルパー遺伝子をコードする核酸配列と、
を含む、前記項目のいずれかのプラスミド。
(項目A3)
前記ウイルスのカプシドタンパク質をコードする核酸配列、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列、
前記ウイルスの2つの末端反復配列、および
ヘルパー遺伝子をコードする核酸配列
のうちの少なくとも2つを含む、前記項目のいずれかのプラスミド。
(項目A4)
前記ウイルスのカプシドタンパク質をコードする核酸配列、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列、
前記ウイルスの2つの末端反復配列、および
ヘルパー遺伝子をコードする核酸配列
のうちの少なくとも3つを含む、前記項目のいずれかのプラスミド。
(項目A5)
前記ウイルスのカプシドタンパク質をコードする核酸配列と、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列と、
前記ウイルスの2つの末端反復配列と、
ヘルパー遺伝子をコードする核酸配列と、
を含む、前記項目のいずれかのプラスミド。
(項目A6)
前記ウイルスベクターを構成するのに必要な核酸配列が、約10kb以上である、前記項目のいずれかのプラスミド。
(項目A7)
前記カプシドタンパク質をコードする核酸配列、前記ゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列および前記ヘルパー遺伝子の少なくとも1つが、前記2つの末端反復配列に挟まれる領域の外にある、前記項目のいずれかのプラスミド。
(項目A8)
枯草菌においてプラスミド複製を促進する前記核酸配列が、枯草菌において作動する複製起点を含む、前記項目のいずれかのプラスミド。
(項目A9)
大腸菌においてプラスミドを増幅する核酸配列をさらに含む、前記項目のいずれかのプラスミド。
(項目A10)
前記ウイルスのカプシドタンパク質をコードする核酸配列が、L1、L2、L3、L4、L5、capおよびgagのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目A11)
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列が、E1A、E1B、E2A、E2B、E4、rep、ψ、APP、MAAP、polおよびrevのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目A12)
前記末端反復配列が、末端逆位反復配列(ITR)または長鎖末端反復配列(LTR)である、前記項目のいずれかのプラスミド。
(項目A13)
前記ヘルパー遺伝子が、E1A、E1B、E2A、E4、VA、env、tat、RPE、PPT、PREおよびproのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目A14)
前記ウイルスのカプシドタンパク質をコードする核酸配列および前記ウイルスのゲノムを転写および複製するタンパク質をコードする核酸配列のうちの少なくとも1つが、アデノウイルスの血清型1~52またはアデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、前記項目のいずれかのプラスミド。
(項目A15)
前記プラスミドが、前記ウイルスの全ゲノムのうち少なくとも一部の遺伝子の配列を含まない、前記項目のいずれかのプラスミド。
(項目A16)
前記ウイルスが、アデノウイルス、アデノ随伴ウイルス、レンチウイルス、レトロウイルスまたはセンダイウイルスである、項目A1~15のいずれか一項に記載のプラスミド。
(項目A17)
前記ウイルスが、アデノ随伴ウイルスまたはレンチウイルスである、前記項目のいずれかのプラスミド。
(項目A18)
前記ウイルスが、アデノ随伴ウイルスである、前記項目のいずれかのプラスミド。
(項目A19)
前記末端反復配列が、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する末端逆位反復配列(ITR)である、前記項目のいずれかのプラスミド。
(項目A20)
5’ITRおよび3’ITRの間に上流からプロモーター、所望の遺伝子およびターミネーターを含む、前記項目のいずれかのプラスミド。
(項目A21)
前記ヘルパー遺伝子が、E1A、E1B、E2A、E4、およびVAのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目A22)
前記ヘルパー遺伝子が、E2A、E4、およびVAを含む、前記項目のいずれかのプラスミド。
(項目A23)
前記ヘルパー遺伝子のそれぞれが、アデノウイルスの血清型1~52およびその改変体のいずれかに由来する、前記項目のいずれかのプラスミド。
(項目A24)
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列が、repを含む、前記項目のいずれかのプラスミド。
(項目A25)
前記repが、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、前記項目のいずれかのプラスミド。
(項目A26)
前記ウイルスのカプシドタンパク質をコードする核酸配列が、capを含む、前記項目のいずれかのプラスミド。
(項目A27)
前記capが、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、前記項目のいずれかのプラスミド。
(項目A28)
前記ウイルスの2つの末端反復配列の間に所望の遺伝子を含む、前記項目のいずれかのプラスミド。
(項目A29)
前記所望の遺伝子が、2~100個の遺伝子である、前記項目のいずれかのプラスミド。
(項目A30)
前記所望の遺伝子が、10~100個の遺伝子である、前記項目のいずれかのプラスミド。
(項目A31)
前記所望の遺伝子が、プロモーター配列を含む、前記項目のいずれかのプラスミド。
(項目A32)
前記プラスミドおよびプロデューサー細胞が、一緒になって前記ウイルスベクターを構成するのに必要な核酸配列を含む、前記項目のいずれかのプラスミド。
(項目A33)
前記プラスミドを導入したプロデューサー細胞から生産される全ウイルスベクター粒子のうち、核酸を含まないウイルスベクター粒子が65%以下である、前記項目のいずれかのプラスミド。
(項目A34)
プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、前記項目のいずれかのプラスミド。
(項目A35)
プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、前記項目のいずれかのプラスミド。
(項目A36)
CCC(covalently closed circular)純度が、80%以上である、前記項目のいずれかのプラスミド。
(項目A37)
所望の遺伝子を発現するための、前記項目のいずれかのプラスミドを含む組成物であって、前記所望の遺伝子は前記プラスミド上で前記ウイルスの2つの末端反復配列の間に配置される、組成物。
(項目A38)
前記項目のいずれかの核酸配列を作動可能に連結するステップを含む、前記項目のいずれかのプラスミドを生産する方法。
(項目A39)
項目A38に記載の方法によって生産されるプラスミド含有組成物。
(項目A40)
プラスミドのCCC(covalently closed circular)純度が、80%以上である、前記項目のいずれかのプラスミド含有組成物。
(項目A41)
前記項目のいずれかのプラスミドを作製するためのキットであって、
枯草菌においてプラスミド複製を促進する核酸配列と、
ウイルスを構成するのに必要な核酸配列と、
を含む少なくとも1つの核酸を含む、キット。
(項目A42)
前記項目のいずれかのプラスミドを含む、ウイルスベクターを調製するための組成物。
(項目A43)
前記項目のいずれかのプラスミドを用いてウイルスベクターを生産するステップを含む、ウイルスベクターを調製するための方法。
(項目A44)
前記プラスミドに含まれる核酸の少なくとも一部が、前記プラスミドを導入したプロデューサー細胞の染色体に組み込まれる、前記項目のいずれかの方法。
(項目A45)
項目A1~36のいずれか一項に記載のプラスミドを用いて生産される、または項目A43または44に記載の方法を用いて生産される、ウイルスベクター。
(項目A46)
前記項目のいずれかのプラスミドを用いて生産される、または前記項目のいずれかの方法を用いて生産される、ウイルスベクター含有組成物。
(項目A47)
全ウイルスベクター粒子のうち核酸を含まないウイルスベクター粒子が65%以下である、前記項目のいずれかの組成物。
(項目A48)
全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、前記項目のいずれかの組成物。
(項目A49)
全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、前記項目のいずれかの組成物。
(項目A50)
前記項目のいずれかのプラスミドを含む枯草菌または大腸菌。
(項目A51)
前記項目のいずれかのプラスミドが導入されたプロデューサー細胞であって、前記プラスミドに含まれる核酸の少なくとも一部が、前記プロデューサー細胞の染色体に組み込まれている、プロデューサー細胞。
(項目1)
枯草菌においてプラスミド増幅を促進する核酸配列と、
ウイルスベクターを構成するのに必要な核酸配列のうちの少なくとも1つと、
を含むプラスミド。
(項目2)
前記ウイルスベクターを構成するのに必要な核酸配列は、
前記ウイルスのカプシドタンパク質をコードする核酸配列と、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列と、
前記ウイルスの2つの末端反復配列と、
ヘルパー遺伝子と、
を含む、前記項目のいずれかのプラスミド。
(項目3)
枯草菌においてプラスミド増幅を促進する前記核酸配列が、枯草菌において作動する複製起点を含む、前記項目のいずれかのプラスミド。
(項目4)
前記ウイルスのカプシドタンパク質をコードする核酸配列が、L2、L3、capおよびgagのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目5)
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列が、E1A、E1B、E2A、E2B、E4、rep、ψ、APP、MAAP、polおよびrevのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目6)
前記末端反復配列が、末端逆位反復配列(ITR)または長鎖末端反復配列(LTR)である、前記項目のいずれかのプラスミド。
(項目7)
前記ヘルパー遺伝子が、E1A、E1B、E2A、E4、VA、env、tat、RPE、PPT、PREおよびproのうちの少なくとも1つを含む、前記項目のいずれかのプラスミド。
(項目8)
前記ウイルスのカプシドタンパク質をコードする核酸配列および前記ウイルスのゲノムを転写および複製するタンパク質をコードする核酸配列のうちの少なくとも1つが、アデノウイルスの血清型1~51またはアデノ随伴ウイルスの血清型1~11のいずれかに由来する、前記項目のいずれかのプラスミド。
(項目9)
前記ウイルスが、アデノウイルス、アデノ随伴ウイルス、レンチウイルス、レトロウイルスまたはセンダイウイルスである、前記項目のいずれかのプラスミド。
(項目10)
前記ウイルスの2つの末端反復配列の間に所望の遺伝子を含む、前記項目のいずれかのプラスミド。
(項目11)
前記所望の遺伝子が、2~100個の遺伝子である、前記項目のいずれかのプラスミド。
(項目12)
前記所望の遺伝子が、プロモーター配列を含む、前記項目のいずれかのプラスミド。
(項目13)
前記プラスミドおよびプロデューサー細胞が前記ウイルスベクターを構成するのに必要な核酸配列を含むようなプロデューサー細胞において機能するように構成される、前記項目のいずれかのプラスミド。
(項目14)
前記プラスミドを導入したプロデューサー細胞から生産される全ウイルスベクター粒子のうち、核酸を含まないウイルスベクター粒子が65%以下である、前記項目のいずれかのプラスミド。
(項目15)
プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、前記項目のいずれかのプラスミド。
(項目16)
プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、前記項目のいずれかのプラスミド。
(項目17)
前記項目のいずれかの核酸配列を作動可能に連結するステップを含む、前記項目のいずれかのプラスミドを生産する方法。
(項目18)
前記項目のいずれかの方法によって生産されるプラスミド含有組成物。
(項目19)
プラスミドのCCC(covalently closed circular)純度が、80%以上である、前記項目のいずれかのプラスミド含有組成物。
(項目20)
前記項目のいずれかのプラスミドを作製するためのキットであって、
枯草菌においてプラスミド増幅を促進する核酸配列と、
ウイルスを構成するのに必要な核酸配列と、
を含む少なくとも1つの核酸を含む、キット。
(項目21)
前記項目のいずれかのプラスミドを含む、ウイルスベクターを調製するための組成物。(項目22)
前記項目のいずれかのプラスミドを用いてウイルスベクターを生産するステップを含む、ウイルスベクターを調製するための方法。
(項目23)
前記項目のいずれかのプラスミドを用いて生産される、または前記項目のいずれかの方法を用いて生産される、ウイルスベクター。
(項目24)
前記項目のいずれかのプラスミドを用いて生産される、または前記項目のいずれかの方法を用いて生産される、ウイルスベクター含有組成物。
(項目25)
全ウイルスベクター粒子のうち核酸を含まないウイルスベクター粒子が65%以下である、前記項目のいずれかの組成物。
(項目26)
全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、前記項目のいずれかの組成物。
(項目27)
全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、前記項目のいずれかの組成物。
(項目28)
前記項目のいずれかのプラスミドを含む枯草菌。
以下に本開示の好ましい実施形態を説明する。以下に提供される実施形態は、本開示のよりよい理解のために提供されるものであり、本開示の範囲は以下の記載に限定されるべきでないことが理解される。従って、当業者は、本明細書中の記載を参酌して、本開示の範囲内で適宜改変を行うことができることは明らかである。また、以下の実施形態は単独でも使用されあるいはそれらを組み合わせて使用することができることが理解される。
一つの局面において、本開示は、枯草菌において複製できるウイルスベクタープラスミドを提供する。1つの実施形態では、本開示は、Bacillus subtilisにおいて複製できるウイルスベクタープラスミドを提供する。これを達成するための任意の手段が本開示の範囲であると企図される。例えば、明示的な記載がなくとも、ある成分を使用する方法の記載は、同成分を含む組成物、同成分の使用および同方法に使用するための同成分など、他の手段を反映した実施形態も同時に企図するものである。
本開示のベクタープラスミドは、ウイルスベクターを生産するために使用される。一つの実施形態において、本開示は、本開示のベクタープラスミドを使用してウイルスベクターを作製する方法を提供する。一つの実施形態において、本開示は、このように作製されたウイルスベクター含有組成物またはウイルスベクターを提供する。ウイルスベクターとしては、レトロウイルス、レンチウイルス、アデノ随伴ウイルス、アデノウイルスまたはセンダイウイルスに基づくウイルスベクターが挙げられる。
アデノウイルスは、アデノウイルス科マストアデノウイルス属のウイルスであり、ウイルス粒子は、ヌクレオキャプシドおよび二本鎖線状DNAゲノムから構成され、90~100nmの正20面体の構造を有する。アデノウイルスの感染は細胞表面のcoxackie-adenovirus receptor(CAR)にウイルスカプシドが吸着することにより開始され、次いで細胞表面のインテグリンを介してウイルスは細胞内に侵入し得る。その後、ライソゾームから脱出したウイルスゲノムは核内に到達しウイルスゲノムの複製をもたらし得る。ウイルス複製は、まずE1A蛋白質が発現し、他の初期蛋白質であるE1B、E2、E3、E4の発現を活性化することで開始される。ウイルスゲノムは、E2から発現した末端タンパク質(TP)とデオキシシチジンとが共有結合し、これにさらにポリメラーゼが結合した複合体が形成されて複製が開始される。ゲノムはまた、ペントン(L2)、ヘキソン(L3)、骨格タンパク質(L4)、および繊維タンパク質(L5)を含む構造タンパク質をコードし、単一プロモーターの制御下にある、5つの後期転写単位(L1、L2、L3、L4、およびL5)も含む。ゲノムの両端は、ウイルスの複製に必要な逆向き末端配列(inverted terminal repeat: ITR)を含む。ウイルスの構造タンパク質は細胞質で翻訳された後、核内に移行してウイルス粒子を構成し、ウイルスゲノムのパッケージングシグナル(ψ)を認識してゲノムをパッケージングする。また、アデノウイルスは、タンパク質非コードVA RNAを生産し、これは、VA遺伝子にコードされている。アデノウイルス粒子は、L2およびL3のカプシドを有し得る。
アデノ随伴ウイルス(AAV)は,パルボウイルス科ディペンドウイルス属の線状一本鎖DNAウイルスであり、ウイルス粒子は直径20~26nmである。AAVの増殖にはアデノウイルスエレメントが必要である。AAVゲノムの量末端にはITR(inverted terminal repeat)と呼ばれるT字型のヘアピン構造が存在する。このITRの部分が複製の開始点となり、プライマーの役割を果たす。また、ウイルス粒子へのパッケージングや宿主細胞の染色体DNAへの組込みにもこのITRが必要である。ゲノムの左半分に非構造蛋白質、すなわち複製や転写を司る調節タンパク質(Rep78、Rep68、Rep52、Rep40)をコードするrep遺伝子が存在し、ゲノムの右半分に構造蛋白質(VP1、VP2、VP3)の三つのカプシドタンパク質をコードするcap遺伝子が存在する。
本明細書において、「レトロウイルス」は、一般にレトロウイルス科のウイルスを指す。トロウイルスは、主にゲノムをRNAからDNAに逆転写する能力を特徴とする二本鎖RNAエンベロープウイルスである。ビリオンの長さは直径約100~120nmであり、ヌクレオキャプシドタンパク質と複合体を形成した同一のプラスRNA鎖の二量体ゲノムを含有する。ゲノムは、ウイルス感染に必要な酵素タンパク質、すなわち逆転写酵素、インテグラーゼおよびプロテアーゼを含有するキャプシドに封入されている。マトリックスタンパク質が、ウイルス核粒子の周りを囲む、宿主細胞膜に由来する脂質二重層であるエンベロープと相互作用するキャプシドコアの外側の層を形成する。この二重層には、宿主細胞上の特異的受容体を認識し、感染プロセスを開始させるウイルスエンベロープ糖タンパク質が固定されている。エンベロープタンパク質は、タンパク質を脂質膜内に固定させる膜貫通(TM)と細胞受容体に結合する表面(SU)の2つのサブユニットによって形成される。
センダイウイルス(SeV)は、パラミクソウイルス科(Paramyxoviridae)レスピロウイルス属(Respirovirus)に分類されるマイナス鎖RNAウイルスである。センダイウイルスはニューロンを含む非分裂細胞にも感染し得る。センダイウイルスの感染後、ウイルスゲノムは宿主細胞の染色体に組み込まれずRNAの状態で細胞質に留まる。
一つの実施形態において、本開示は、複数の核酸配列を作動可能に連結するステップを含む、本開示のベクタープラスミドを作製する方法を提供する。一つの実施形態において、本開示は、本開示のベクタープラスミドを枯草菌において複製するステップを含む、本開示のベクタープラスミドを作製する方法を提供する。一つの実施形態において、本開示は、枯草菌内で複製される配列を有する、ウイルスベクターを生産するための核酸配列を含む核酸を宿主細胞に導入して、前記宿主細胞においてプラスミドを形成させるステップを含む、本開示のベクタープラスミドを作製する方法を提供する。本明細書において、一つの実施形態において、枯草菌は外部から取り込んだ核酸からプラスミドを形成する能力を有し得るので、この方法において、導入する核酸はプラスミドでなくてもよい。例えば、枯草菌は、核酸(例えば、タンデムリピートな核酸配列を有する非環状核酸)と接触すると、この核酸を取り込み、枯草菌内でプラスミドを形成し得る(例えば、本明細書に記載のOGAB法を参照のこと)。
一つの実施形態において、本開示のベクタープラスミドは、OGAB法によって作製され得る。OGAB(Ordered Gene Assembly in Bacillus subtilis)法は、集積核酸を形質転換生物に取り込ませることでこの生物において環状のプラスミドを生成する方法である。OGAB法は、必ずしも枯草菌(Bacillus subtilis)を使用する必要はなく、非環状の長鎖核酸を取り込み、プラスミドを生成できる任意の生物を使用でき、このような生物を本明細書では「形質転換生物」と呼ぶ。OGAB法では、大きなサイズの核酸を含むプラスミドが簡便に調製され得る。形質転換生物に取り込ませる核酸を本明細書では「集積核酸」と呼び、典型的には、集積核酸は、同じ方向にプラスミドの1単位と、1セットの単位核酸とが繰り返し現れるようなタンデムリピート状の構造を有し、このような構造の集積核酸を使用することで、形質転換生物におけるプラスミドの生成が促進され得る。本明細書において「単位核酸」とは、集積核酸の配列を構成する一部の配列を有する核酸分子または核酸分子の部分を指し、以下で詳細に説明されるように、複数種類の単位核酸が単位ベクターとして調製され、その後集積核酸が構築される。
集積核酸に組み込むための単位核酸を調製する。単位核酸は任意の公知の方法によって作製でき、例えば、ポリメラーゼ連鎖反応(PCR)や化学合成により作製することができる。単位核酸は、所望のタンパク質(治療用タンパク質、ウイルスベクターを構成するタンパク質など)をコードする配列またはその部分、遺伝子を制御する配列(プロモーター、エンハンサーなど)、核酸を操作するための配列(制限酵素認識配列など)など任意の所望の配列を有し得る。集積核酸に組み込んだときに、複数種類の単位核酸が特定の順番および/または特性の方向に並ぶように、それぞれの単位核酸の末端は、特定の突出配列を生じるように構成され得る。
単位核酸と、それとは異なる付加核酸とを連結することで単位ベクターを調製することができる。単位ベクターを使用することで、単位核酸をより容易に取り扱うことが可能になり得る。
集積核酸は、単位核酸を互いに連結することによって構築され得る。一つの実施形態において、単位核酸は、単位ベクターから制限酵素などによって切り出されることで調製され得る。集積核酸は、反復配列のセットを1つ以上、2つ以上、3つ以上、4つ以上、5つ以上、6つ以上、7つ以上、8つ以上、9つ以上または10つ以上含み得る。集積核酸における反復配列は、単位核酸の配列および必要に応じて集積ベクター核酸の配列を含み得る。集積核酸は、形質転換生物において核酸の複製を可能とする配列を有し得る。一つの実施形態において、形質転換生物において核酸の複製を可能とする配列は、形質転換生物(例えば、Bacillus属細菌(枯草菌))中で有効な複製開始点を含み得る。枯草菌中で有効な複製開始点の配列は、特に限定されないが、例えば、θ型の複製機構を有するものとしては、pTB19(Imanaka,T., et al. J.Gen.Microbioi. 130, 1399-1408.(1984))やpLS32(Tanaka, T and Ogra, M. FEBS Lett. 422, 243-246.(1998))、pAMβ1(Swinfield, T.J., et al. Gene 87, 79-90.(1990))等のプラスミドに含まれる複製開始点等の配列が挙げられる。
集積核酸を形質転換生物と接触させることで、形質転換生物においてプラスミドが形成され得る。一つの実施形態において、形質転換生物として、Bacillus属細菌、Streptococcus属細菌、Haemophilus属細菌、Neisseria属などが挙げられる。Bacillus属細菌としては、B.subtilis(枯草菌)、B.megaterium(巨大菌)、B.stearothermophilus(中度高熱菌)などが挙げられる。好ましい実施形態において、形質転換生物は枯草菌である。一つの実施形態において、集積核酸を取り込ませる形質転換生物は、コンピテント状態であり、能動的に核酸を取り込むことができる。例えば、コンピテント状態の枯草菌は、基質となる2本鎖核酸を細胞上で切断し、2本鎖の内のいずれかの1本鎖をこの切断点から分解し、他方の1本鎖を菌体内に取り込む。取り込まれた1本鎖は、菌体内で環状の2本鎖核酸に修復され得る。形質転換生物をコンピテント状態にするために、任意の公知の方法を使用できるが、例えば、枯草菌は、Anagnostopoulou, C. and Spizizen, J. J. Bacteriol., 81, 741-746(1961)に記載の方法を用いてコンピテント状態にすることができる。形質転換の方法は、それぞれの形質転換生物に適した公知の方法を用いることができる。
一つの実施形態において、本開示は、本明細書に記載のベクタープラスミドまたはウイルスベクターを含む組成物を提供する。
本明細書に記載される組成物は、種々の形態で提供され得る。組成物の形態としては、例えば、注射剤、カプセル剤、錠剤、顆粒剤、吸入剤等であってもよい。注射用の水溶液は、例えば、バイアル、またはステンレス容器で保存してもよい。また注射用の水溶液は、例えば生理食塩水、糖(例えばトレハロース)、NaCl、またはNaOH等を配合してもよい。
本明細書に記載のベクタープラスミドまたはウイルスベクター、またはこれらを含む組成物は遺伝子治療、機能的ゲノム学、癌ワクチン接種および/または抗ウイルスワクチン接種など、種々の用途で使用することができる。
以下の手順に従ってAAVベクタープラスミドを作製し、大腸菌および枯草菌で増幅した。
pAAV-CMVベクター、pRC2-mi342ベクター、pHelperベクターのプラスミド(AAVpro(登録商標)Helper Free System)は、タカラバイオ(滋賀県)より購入した。枯草菌-大腸菌間シャトルプラスミドベクターであるpGETS103ΔAarIは、プラスミドpGETS103(Tsuge, K., Itaya, M. (2001) Recombinational transfer of 100-kilobase genomic DNA to plasmid in Bacillus subtilis 168, Journal of Bacteriology, 183, 5453-5458.)における唯一の制限酵素AarI認識部位(5’-CACCTGC-3’)に点突然変異(5’-CACCAGC-3’)を導入することによりAarI認識部位を消失させたプラスミドであり、神戸大学より譲渡を受けた。大腸菌JM109株のケミカルコンピテントセルは、タカラバイオより購入した。枯草菌BUSY9797株(Tsuge, K., Sato, Y., Kobayashi, Y., Gondo, M., Hasebe, M., Togashi, T., Tomita, M., Itaya, M. (2015) Method of preparing an equimolar DNA mixture for one-step DNA assembly of over 50 fragments, Scientific Reports, 5, 10655.)は、神戸大学より譲渡を受けた。TAクローニング用ベクターのpMD19-Tv-vector、DNA Ligation Kit <Mighty Mix>は、タカラバイオより購入した。制限酵素AarIは、Thermo Fisher Scientific(米国)から購入した。その他の制限酵素は全てNew England Biolab(米国)より購入した。TE緩衝液(10mM Tris-HCl、1mM EDTA、pH8.0)は、ナカライテスク(京都)より購入した。カルベニシリンおよびテトラサイクリンは、シグマアルドリッチ(米国)より購入した。低融点アガロースとして、2-ヒドロキシエチルアガロース(シグマアルドリッチ)を用いた。他の一般的な電気泳動用アガロースゲルは、インビトロジェン(米国)のUltraPure Agaroseを使用した。フェノール飽和TEは、ナカライテスクより購入した。プラスミドのカラム精製キットとして、キアゲン(ドイツ)のQIA quick miniprepキット、およびPCR purification Kitを用いた。Bactotryptone、Yeast extract、Bacto Agarは、ベクトン・ディッキンソン(米国)より購入した。その他の培地用試薬は、ナカライテスクより購入した。卵白リゾチーム、エチジウムブロマイドは、シグマアルドリッチより購入した。リボヌクレアーゼAは、ナカライテスより購入した。プラスミド精製に用いる、P1、P2、P3は、キアゲンより購入した。塩化セシウムは、ナカライテスクより購入した。
LB培地は、Bactotryptone 10g、Yeast extract 5g、塩化ナトリウム5gを1Lの水に溶解し、寒天プレートを形成する場合は、さらにBacto Agar 15gを添加し、オートクレーブ(121℃、20分)したものを使用した。必要に応じて、カルベニシリン(終濃度100μg/ml)、あるいはテトラサイクリン(終濃度10μg/ml)を加えた。枯草菌形質転換用のTF-1培地およびTF-II培地は、以下のように調製した。まず、10×Spizizen(1Lあたり、140g K2HPO4(無水)、60g KH2PO4(無水)、20g (NH4)2SO4)、10g Na3シトレート・2H2O)、50%グルコース、2% MgSO4・7H2O、2%カザミノ酸および水を、それぞれオートクレーブして個別に準備した。トリプトファン、アルギニン、ロイシン、トレオニンの各アミノ酸の水溶液(5mg/ml)は、フィルター滅菌により準備した。TF-I培地500mlの調製のためには、10×Spizizenを50ml、50%グルコース、2% MgSO4・7H2O、2%カザミノ酸、5mg/mlのトリプトファン、アルギニン、ロイシン、トレオニンの各アミノ酸を、それぞれ5mlづつ使用し、最後に滅菌水415mlを混合して、フィルターろ過し、使用までは4℃で保存した。TF-II培地500mlの調製については、2%カザミノ酸を2.5ml、各アミノ酸溶液(5mg/ml)を0.5ml、滅菌水を435.5mlにした以外は、TF-I培地と同様の量を加えてフィルターろ過し、使用まで4℃で保存した。
他の一般的なDNAの操作については、標準プロトコル(Sambrook, J., et al., Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York(1989))に従って行った。
増幅したDNA断片は、0.7%の低融点アガロースゲル(2-Hydroxyethyl Agarose TypeVII、シグマアルドリッチ)で、1×TAEバッファー(Tris-Acetate-EDTA Buffer、ナカライテスク)存在下で、汎用アガロースゲル電気泳動装置(i-MyRun.N 核酸用電気泳動システム、コスモバイオ(東京))において、100V(約8V/cm)の電圧を印加し、1時間泳動することにより、ベクタープラスミドおよび単位DNAを分離した。この泳動ゲルを、1μg/mlのエチジウムブロマイドを含む1×TAEバッファー100mlで30分間染色し、長波長の紫外線(366mn)を照射して可視化することで、目的サイズのPCR産物をカミソリで切り出し、1.5mlチューブに回収した。回収した低融点アガロースゲル(約300mg程度)に1×TAEバッファーを添加して全体積を約700μlとし、これを65℃で10分間インキュベートすることにより、ゲルを溶解した。その後、等量のTE飽和フェノールを添加し、よく混合することで制限酵素を失活させた。遠心分離(20,000×g、10分間)によりフェノール相と水相とに分離し、水相(約900μl)を新しい1.5mlチューブに回収した。ここに1-ブタノールを500μl添加し、よく混合した後、遠心分離(20,000×g、1分間)により分離し、水分が飽和した1-ブタノール相を取り除くという操作を水相の体積が450μl以下になるまで繰り返すことで、水相の体積を減少させた。これに、3M酢酸カリウム-酢酸緩衝液(pH5.2)50μlおよびエタノール900μlを添加し、遠心分離(20,000×g、10分間)することにより、DNAを沈殿させ、これを70%エタノールでリンスして、20μlのTE緩衝液に溶解した。この回収DNAは、使用まで-20℃で保存した。
pAAV-CMVプラスミド(図1)、pRC2-mi342プラスミド(図2)、pHelperプラスミド(図3)から制限酵素による切り出しなどによって取得した必要な断片(pAAV-CMVからは1.8kbのSbfI断片、pRC2-mi342からは5.2kbのEagI-XmaI断片、pHelperからは9.3kbのBamHI-BamHI-NdeI断片)を、集積用のプラスミドに連結することで組換えプラスミドを構築した。pHelper内のVA領域内にBamHIサイトが存在していることから、このBamHIサイトと近傍のNdeIサイトまでの0.3kbの断片は、PCRで増幅して取得した。この断片を、上記の3つの断片を導入可能なように、SbfIサイト、AarIサイト、EagI-XmaIサイトを導入したプライマーを使用して増幅することで、配列番号1に示す配列を有するPCR産物を得た。
溶解した大腸菌JM109コンピテントセル50μlを氷上に準備した1.5mlの遠心チューブに移し、これに組換えプラスミドを最大で5μlとなるように添加し、氷上に15分静置後、42℃の温浴で45秒インキュベーション後、氷上に戻して2分経過後に、コンピテントセルに付属しているSOC培地を200μl添加し、回転培養装置(RT-50に試験管用培養ホルダーSA-1811を搭載、タイテック(大阪))にセットし、30rpmの回転速度で37℃で1時間培養した。その後、これを、カルベニシリン入りLB培地寒天プレートに塗抹し、37℃で一晩培養した。
Falcon(登録商標)の14ml試験管(2051)にLB培地2mlを入れ、そこに、-70℃で保存したグリセロールストックの枯草菌を植菌し、回転培養装置で回転しながら、37℃で17時間培養した。新しい14ml試験管(Falcon 2051)にTF-I培地を900μl分注し、25μlの2%カザミノ酸を添加し、50μlの上記培養液を添加し、回転培養装置で回転しながら、37℃で4時間培養した。その後、新しい14ml試験管にTF-II培地を900μl分注し、100μlのTF-I培養液を添加し、回転培養装置で回転しながら、37℃で1.5時間培養した。1.5mlの遠心チューブにTF-II培養液を100μl入れ、8μlの組換えプラスミドを添加した。回転培養装置で回転しながら、37℃で30分培養した後、LB培地を300μl添加し、さらに回転培養装置で回転しながら、37℃で1時間培養した。その後、培養物を、テトラサイクリン10μg/mlを含むLB培地寒天プレート上に広げて、37℃で一晩インキュベーションすることで、形質転換体を得た。
大腸菌内で構築した組換えプラスミドの構造確認のための少量精製は、キアゲンのQIAprep Spin Miniprep Kit、および自動化装置であるQIA cubeを用いてマニュアルに従い行った。
塩化セシウムーエチジウムブロマイド密度勾配超遠心法により高純度のプラスミドDNAを調達した。以下は、LB培地200mlの場合の精製方法を示すが、200mlを超える場合は、200mlごとに以下の操作を繰り返して行った。LB培地に抗生物質(テトラサイクリン)を加えたものを200ml用意し、500mlの三角フラスコに100mlずつ入れて、大腸菌もしくは枯草菌プラスミド保持株を接種し、37℃で終夜培養した。
大腸菌および枯草菌で増幅したベクタープラスミドをプロデューサー細胞に導入し、AAVベクターを生産させた。この実施例の実験は、SignaGen Laboratories(米国)に依頼して実施した。
rAAVの作製に用いたプラスミドDNAのCCC(covalently closed circular)純度を、P/ACE MDQ Plus(SCIEX)およびdsDNA 1000 kit(AB SCIEX、東京)を用いて定量した。キットに含まれるゲル粉末に超純水を20mL加え、終夜撹拌した。ゲルが完全に溶解したことを確認し、1xTBE electrophoresis buffer(Thermofisher)で10倍希釈した。希釈したゲルに、0.01vol%となるようSYBR Gold nucleic acid gel stain(Thermofisher)を加えた後、キャピラリーにゲルを充填した。各プラスミドDNAは、超純水で10ng/μLに調整し、P/ACE MDQ Plusを用いて測定した。
SignaGenで凍結保存された各rAAVを解凍し、Step One plus(Thermofisher)を用いて、rAAVゲノムに対して定量PCRを行った。250U/mLに調製したDNaseI(タカラバイオ)と作製したrAAVとを等量混合後、PCR用サーマルサイクラー(Thermofisher)を用いて37℃で30分間加熱した。次いで、0.04MのEDTAバッファー(pH8.0、タカラバイオ)を添加し2倍希釈し、55℃で30分間加熱した。さらに、ヌクレアーゼフリーの水(Promega)で2.5倍希釈し、95℃で10分間加熱した。最後に、TEバッファー(Promega)を加えて10倍希釈を行い、抽出したrAAVゲノムを定量PCR用のテンプレートとして用いた。
SignaGenで凍結保存された各rAAVを解凍し、Step One plusを用いて、プラスミドバックボーンに含まれるAmpr遺伝子に対して、定量PCRを行った。作製したrAAVにTEバッファーを加え3倍希釈した後、PCR用サーマルサイクラーを用いて95℃で10分間加熱した液を、抽出したrAAVゲノムを定量PCR用のテンプレートとして用いた。
SignaGenで凍結保存された各rAAVを解凍し、ARVO X5(パーキンエルマー)を用いて、ELISA法にてカプシド粒子濃度の定量を行った。定量キットには、AAV2 Titration ELISA 2.0R(PROGEN)を利用し、プロトコルに基づき試験を実施した。キットに含まれる抗AAV2抗体が固定化された96ウェルプレートに、rAAVおよび標準品(キットに含まれる空カプシド試薬)を100μLずつ添加した。37℃で1時間静置後、液を廃棄し、200μLのアッセイバッファーで3回洗浄した。100μLのビオチン結合抗AAV2抗体を添加し、37℃で1時間静置後、液を廃棄し、200μLのアッセイバッファーで3回洗浄した。さらに、100μLのHRP標識済みのストレプトアビジンを添加し、37℃で1時間静置後、液を廃棄し、200μLのアッセイバッファーで3回洗浄した。最後に、100μLのTMBを添加し、室温で15分間静置後、反応停止試薬を加えて、ARVO X5で吸光度(450nm、650nm)を測定した。
OGAB法によりpGETS103-AAV-Helper-RC2を構築した(図10)。
プラスミドpGETS103ΔAarIを制限酵素HindIIIで切断し、TE飽和フェノール処理、ブタノール抽出、エタノール沈殿で精製し、これに配列番号3および4で示される一本鎖DNAをアニールして作製したリンカーDNAを挿入して、OGAB集積用ベクターであるpGETS103-ΔAarI-Linkerを作製した。このプラスミドを制限酵素AarIで切断し、低融点アガロースゲル電気泳動によりサイズ分離し、大きい15kbの断片をゲルから切り出し、精製して、OGAB集積用のベクター断片を取得した。
pGETS103-AAV-Helper-RC2の塩基配列のうち、ベクター部分のpGETS103の塩基配列を除くAAV-Helper-RC2の領域(図10)について、OGAB法による再構成が可能かどうかを検討した。まず、上記DNA領域を図10に示す22個の断片に分割するように設計した。第3断片はAAV断片とHelper断片の境界の領域を含み、第16断片はHelper断片とRC2断片の境界の領域を含むため、第1、第3および第16断片は、以下に示すように材料のDNAを化学合成後、MAP法(特願2018-93024)により準備した。具体的には、第1断片については配列番号5~10の、第3断片については配列番号11~16の、第16断片については配列番号17~22の、一本鎖DNAを用いて、MAP法によりアセンブリして得られた二本鎖DNAを用いた。残りの領域については、配列番号23~66に示す各断片の番号の付くFとRのプライマーの組み合わせを用いて、第2断片についてはpAAV-CMV Vectorを、第4~第15断片はpHelper Vectorを、第17~第22断片についてはpRC2-mi342 Vectorをテンプレートとして以下の条件によりPCRにより増幅した。一反応あたり、10μlの2×Prime Star mix(タカラバイオ)、1μlのテンプレートDNA、両方のプライマーを3.2pmolずつ含む1μlの溶液、8μlの滅菌水を加えて、96℃2分ののち、98℃10秒、55℃15秒、72℃5秒のサイクルを30サイクル行った。
DNA断片をMAP法、もしくはPCR法により得たのち、これらのDNAをMinElute PCR Purification Kit(キアゲン)を用いて精製し、最終的に15μlのTE緩衝液(ナカライテスク)によりカラムから溶出した。得られたDNA溶液の1.4μlに0.2μlの10×Ex-Taq buffer(タカラバイオ)、0.2μlの2mM dNTP(タカラバイオ)、0.2μlの10xA-attachment mix(TOYOBO)を加えて、60℃で1時間反応させた。その後、1μlのpMD19 simple(タカラバイオ)をTE緩衝液で20倍に希釈して、3μlのDNA Ligation Kit <Mighty Mix>を加えて、16℃で3時間ライゲーション反応を行い、大腸菌JM109コンピテントセル(タカラバイオ)を用いて形質転換を行った。終夜培養後、カルベニシリン入りLBプレートに出現したコロニーについて塩基配列を確認することで、それぞれの断片について正しい配列のクローンを取得した。
これらのクローンを持つ大腸菌を2mlのLB培地で増殖後、その900μlを用いてQIAprep Spin Miniprep Kit(キアゲン)により、自動化システムQIAcubeによりプラスミドを精製し、最終的に30μlのTE緩衝液に溶出した。そのうちの2.5μg相当のプラスミドDNAを含む溶液を50μlになるようにTE緩衝液を添加した。さらにそこに、6μlの10XPlasmid safe buffer(epicentre)、2.4μlの25mM ATP、2μlのPlasmid-Safe ATP-Dependent DNase (epicentre)を加えて、37℃1時間反応後、70℃30分失活させることで、環状構造以外のDNAを分解した。その後、反応液をMinElute PCR Purification Kit(キアゲン社)を用いて精製し、最終的に15μlのTE緩衝液(ナカライテスク)によりカラムから溶出した。得られたDNA溶液を微量分光光度計(Nano drop One、Thermofisher)を用いて測定し、100ng/μlとなるようにTE緩衝液を加えて希釈した。その後、再度濃度を測定し、正確に500ngのDNAを分取する際に必要なDNA体積を小数点以下2桁μlまで計算して、マイクロピペットにより分取することで各プラスミドの等モル分取を行った。分取したDNA溶液は、その後に使用する制限酵素の種類により2つの1.5mlの遠心チューブに分けてプールした。第1、3、5、7、9、11、13、14,17、19、21断片をクローン化するプラスミドは、制限酵素AarIで切断するチューブへ、第2、4、6、8、10、12,15、16、18、20、22断片をクローン化するプラスミドは、制限酵素BsaIで切断するグループにそれぞれプールした。その後、AarIで切断するチューブには、各プラスミドの容積の合計を1体積とした場合に、1.94体積の滅菌水、0.33体積の10×Buffer AarI(Thermofisher)、0.06体積の50×オリゴヌクレオチド(0.025mM)、0.17体積のAarI(Thermofisher)を加えて37℃で2時間反応させた。また、BsaIで切断するチューブには、各プラスミドの容積の合計を1体積とした場合に、2体積の滅菌水、0.33体積の10XCutSmart buffer(NEB)、0.17体積のBsaI-HF v2を加えて37℃で2時間反応させた。それぞれのチューブに制限酵素反応液と等量のTE飽和フェノールを添加して、よく混合することで制限酵素を失活させた後、乳化した状態のフェノールとDNA溶液の混合物を一つの2ml遠心チューブに統合して、20,000×gで10分間遠心し、フェノール相と水相とに分離した。上層を新しいチューブに移して、そこに等量の1-ブタノールを加え、よく撹拌し、20,000×gで1分間遠心した。その後、上層をピペットで吸って取り除き、下層の体積が450μl以下になるまで、再度等量の1-ブタノールを加えて、遠心、上層を捨てる、の操作を繰り返した。その後、50μlのP3バッファーを加えて、900μlのエタノールを加え、20,000×gで10分間遠心した。沈殿を失わないように上清を捨てたのち、900μlの70%エタノールでリンス後、上清をピペットで吸って捨てた。その後、再度遠心し、残っている上清を底部に集めて、ピペットで完全に液体を取り除いた。直ちに、TE50μlを加えて沈殿を5分間タッピングすることで完全に溶解した。その後、低融点アガロースゲルによる電気泳動によりpMD19から切り出された約750bpの22種類の断片の等モル混合物をサイズ分画し、実施例1に記載の電気泳動ゲルからのDNA断片の切り出しと精製の方法に従って、22種類の断片の混合物を精製した。
その後、得られたDNA溶液の1fmolと、AarIで切断し精製したpGETS103ΔAarI-Linkerの1fmolとに合計4μlとなるようにTE緩衝液を追加し、そこに5μlの2×ライゲーションバッファー(15%ポリエチレングリコール6000、500mM NaCl、132mM Tris・HCl(pH7.6)、13.2mM MgCl2、20mM DTT、0.2mM ATP)を添加してよく混合後、1μlのT4 DNA Ligase(タカラバイオ)を加え、37℃で5時間インキュベーションした。ここに枯草菌コンピテントセル100μlを添加し、37℃で、30分ダックローターにより回転培養した。その後、300μlのLB培地を添加して、37℃で1時間ダックローターで回転培養し、その後、培養液を10μg/mlのテトラサイクリン(シグマアルドリッチ)入りLBプレートに広げ、37℃で一晩培養した。コロニーは94個得られた。
ランダムに12株のコロニーを選択して、2mlの10μg/mlのテトラサイクリン入りLB培地で一晩培養し、内部のプラスミドのコピー数を増幅するためにIPTGを終濃度1mMとなるように添加して更に37℃で3時間培養した。得られた菌体から以下の様に少量のプラスミド抽出を行った。900μlの菌液を1.5ml遠心チューブにとり、6800×gで3分遠心し、上清をマイクロピペットで取り除いた。得られた菌体ペレットをよく懸濁後、10mg/mlの卵白リゾチーム(wako)を含むP1バッファーを100μl添加後、37℃で5分間インキュベーションした。そこに、200μlのP2バッファーを加えて4回転倒混和した。その後、P3を150μl添加し、4回転倒混和した。これを20,000×gで、10分間遠心することにより、白い沈殿と上清に分離した。上清を新しい1.5ml遠心チューブに移して、そこに、450μlのTE飽和フェノール(ナカライテスク)を添加し、良く混和した後、20,000×gで、10分間遠心することにより、フェノール相と水相とに分離し、水相320μlを新しいチューブに移して、そこに900μlのエタノールを加え、20,000×gで、10分間遠心した。上清をマイクロピペットで取り除き、900μlの70%エタノールを加え、チューブ全体をリンスした。その後、70%エタノールをマイクロピペットで取り除き、得られた沈殿を27μlのTE緩衝液で溶解した。得られたプラスミド溶液を8μlとり、そこに1μlの10×3.1 NEB buffer(NEB)と、1μlのSmaIを添加し、37℃で1時間反応後、アガロースゲル電気泳動により切断バターンを確認した。図11に示すように、12個中1個(クローン番号3)が期待した切断パターンを示した。このクローンについて、全塩基配列を決定したところ、pGETS103-AAV-Helper-RC2を再構成していることを確認した。
同様に、AAVウイルスベクターを生産するためのオールインワン構造の7種類のベクタープラスミドを、他の血清型のAAVゲノムおよびアデノウイルスゲノムから取得した構成要素を使用して構築した。pGETS118-AarI(Tsuge, K., Sato, Y., Kobayashi, Y.,Gondo,M., Hasebe,M., Togashi,T., Tomita, M., and Itaya, M. Method of preparing an equimolar DNA mixture for one-step DNA assembly of over 50 fragments. Sci Rep 5, 10655 (2015).)に基づき各プラスミドを構築した(図16に模式図を示す)。ベクタープラスミドの各々において使用したITR、Rep、CapおよびHelper(VA、E2AおよびE4)の由来となるウイルスゲノムの血清型を以下の表に示す(図17も参照のこと)。
AAV:アデノ随伴ウイルス血清型
Ad:アデノウイルス血清型および群
アデノウイルスベクターAd5について、タカラバイオ社のpAxCAwtit2にGIO遺伝子を導入した全長約36kbのアデノウイルスベクターを生産するためのオールインワン構造を設計した(図19)。これを40個の約800bpに分割し、PCRまたは化学合成により単位DNA断片を含むDNA断片を調製した。これらのDNA断片を、AarI、BbsI、BsaI、BsmBIのいずれかの制限酵素により切り出して単位DNA断片を調製した。その後、AarIで切断したpGETS118-AarI、またはpBET131(Tanaka, T., and M. Ogura.1998. A novel Bacillus natto plasmid pLS32 capable of replication in Bacillus subtilis. FEBS Lett.422:243-246)のBamHIサイトにリンカーDNAを導入して新たなAarIサイトを2か所導入したpBET131―AarI(図20)をAarIで切断して得られる2つの大きい断片とタンデムリピートに連結し、その後、上の実施例と同様にOGAB法により枯草菌において環状のプラスミドを形成させた。その結果、アデノウイルスベクターを生産するためのオールインワン構造を有するクローンの構築が確認された。
図21~26に示すAAVウイルスオールインワンベクタープラスミドも企図される。
・図21は、pGETS103-ΔAarIに基づくAAV1のRepおよびAAV6のCapを使用した構築例である。
・図22は、pGETS103-ΔAarIに基づくCAGプロモーター、AAV5のRepおよびAAV1のCapを使用した構築例である。
・図23は、pGETS103-ΔAarIに基づくEF1αプロモーター、AAV8のRepおよびAAV9のCapを使用した構築例である。
・図24は、pGETS103-ΔAarIに基づくSV40プロモーターを使用し、Rep、CapおよびHelperを異なる順序で配置した構築例である。
・図25は、pGETS131-AarIに基づくRep、CapおよびHelperを異なる順序で配置した構築例である。
・図26は、pBETS103-ΔAarIに基づくHelper遺伝子の要素を変更した(他の要素と分離してアデノウイルスE1AおよびE1Bを追加した)構築例である。
AAVウイルスベクタープラスミドは、HEK293以外のプロデューサー細胞(NIH3T3、HT1080、A549、HeLa、HEK 293Tなど)を使用する場合には、上記の実施例の構造に加えて、さらにE1AおよびE1B遺伝子を含むように構築することができる。
pGETS103ΔAarIをベースに以下の核酸配列を追加してベクタープラスミドを構築する。
・CMVプロモーター、VSV-G(水疱性口内炎ウイルスの糖タンパク質G)、ポリA・CMVプロモーター、rev、ポリA
・5’LTR、Ψ(パッケージングシグナル配列)、RPE、PPT、CMVプロモーター、WPRE、3’LTR
・CMVプロモーター、gag、pol、RPE、ポリA
(所望の遺伝子はLTR間でプロモーターの下流に位置付けられ得る。)
pGETS103ΔAarIをベースに以下の核酸配列を追加してベクタープラスミドを構築する。
・CMVプロモーター、env、ポリA
・5’LTR、Ψ(パッケージングシグナル配列)、RPE、PPT、CMVプロモーター、WPRE、3’LTR
・CMVプロモーター、gag、pol、RPE、ポリA
(所望の遺伝子はLTR間でプロモーターの下流に位置付けられ得る。)
pGETS103ΔAarIをベースに以下の核酸配列を追加してベクタープラスミドを構築する。
・CAGプロモーター、T7 RNAポリメラーゼ
・CAGプロモーター、N
・CAGプロモーター、P、L、F
・T7プロモーター、Fを欠失させたセンダイウイルスゲノム、Rbz
(所望の遺伝子はセンダイウイルスゲノムのいずれかの遺伝子の間に位置付けられ得る。)
pGETS103ΔAarIをベースに以下の核酸配列を追加してベクタープラスミドを構築する。
・5’ITR、アデノウイルス血清型5のゲノム(E1遺伝子の部位をプロモーターおよびE1A遺伝子で置換する)、3’ITR
(E1A遺伝子に加えて、所望の遺伝子も上記または他のプロモーターの下流に位置付けられ得る。)
コロナウイルスベクタープラスミドを、pGETS103ΔAarIをベースに以下の核酸配列を追加して構築する。
・非構造タンパク質領域のORF1a、非構造タンパク質領域のORF1bおよび構造タンパク質領域を含み、構造タンパク質領域に所望の遺伝子を含む。構造タンパク質領域のスパイク遺伝子S、エンベロープ遺伝子E、マトリックス遺伝子M、ヌクレオカプシド遺伝子N等は必要に応じて欠損させてもよい。
以上のように、本開示の好ましい実施形態を用いて本開示を例示してきたが、本開示は、特許請求の範囲によってのみその範囲が解釈されるべきであることが理解される。本明細書において引用した特許、特許出願および文献は、その内容自体が具体的に本明細書に記載されているのと同様にその内容が本明細書に対する参考として援用されるべきであることが理解される。
tagGGTCTCaAGCTtgCCTGCAGGcaGATCatgcgcaggtgcacctgcatgcGATCCGGGGTTCGAACCCCGGTCGTCCGCCATGATACCCTTGCGAATTTATCCACCAGACCACGGAAGAGTGCCCGCTTACAGGCTCTCCTTTTGCACGGTCTAGAGCGTCAACGACTGCGCACGCCTCACCGGCCAGAGCGTCCCGACCATGGAGCACTTTTTGCCGCTGCGCAACATCTGGAACCGCGTCCGCGACTTTCCGCGCGCCTCCACCACCGCCGCCGGCATCACCTGGATGTCCAGGTACATCTACGGATTACGTCGACGTTTAAACCATATGAGCGGCCGCatatatCCCGGGAGCTaGAGACCtca
配列番号2:pGETS103-AAV-Helper-RC2
(配列表に記載の通り)
配列番号3:リンカーF
AGCTTGCGCAGGTGCACCTGCATGCGG
配列番号4:リンカーR
AGCTCCGCATGCAGGTGCACCTGCGCA
配列番号5:第1-1
TAGAGGCAAGGGTTGTTTTTATTGACTACACCTGCGATCAAGCTTGCCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGG
配列番号6:第1-2
GGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCGGAACTCCATATATGGGCTATGAACTAATGACCCCGTAATTGATTACTATTAAAGCTTGATATCGATAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCT
配列番号7:第1-3
ATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCAT
配列番号8:第1-4
GTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGC
配列番号9:第1-5
GTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACT
配列番号10:第1-6
TACTGGTTGGAAGAAAGACCTCTATCACCTGCGATCCTGGGCCCTTAAGGATATCCACTAAACCAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAAAC
配列番号11:第3-1
TAGAGGCAAGGGTTGTTTTTATTGACTACACCTGCGATCGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTT
配列番号12:第3-2
AGGGAGCAGTGGTTCACGCCTGTAATCCCAGCAATTTGGGAGGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCCTGGCCAATATGGTGAAACCCCGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCATGC
配列番号13:第3-3
GGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTATCGATAGATCTAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGG
配列番号14:第3-4
GGAAGCTGTAGAGCTGTTCCTGGTTGCGACGCAGGGTGGGCTGTACCTGGGGACTGTTAAGCATGGAGTTGGGTACCGGATCTGCCTGCAGGCAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACC
配列番号15:第3-5
CGCAACCAGGAACAGCTCTACAGCTTCCTGGAGCGCCACTCGCCCTACTTCCGCAGCCACAGTGCGCAGATTAGGAGCGCCACTTCTTTTTGTCACTTGAAAAACATGTAAAAATAATGTACTAGGAGACACTTTCAATAAAGGCAAATGT
配列番号16:第3-6
TACTGGTTGGAAGAAAGACCTCTATCACCTGCGATCTGTCCCTGCCAGTGGCGCATAGCGATGCGCGGCAGAACCCCTTTGATTTTTAAACGGCGCAGACGGCAAGGGTGGGGGGTAAATAATCACCCGAGAGTGTACAAATAAAAACATTTGCCTTTATTGAAAGTGTCTCCT
配列番号17:第16-1
TAGAGGCAAGGGTTGTTTTTATTGACTAGGTCTCGCAGGTACATCTACGGATTACGTCGACGTTTAAACCATATGAGCGGCCGCTCTAGAACTAGTGGATCCCCCGGAAGATCAGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGTATAGGAACTTCTGATCTGCGCAGCCGCC
配列番号18:第16-2
CAGAATCTGGCGGCAACTCCCATTCCTTCTCGGCCACCCAGTTCACAAAGCTGTCAGAAATGCCGGGCAGATGCTCGTCAAGGTCGCTGGGGACCTTAATCACAATCTCGTAAAACCCCGGCATGGCGGCTGCGCAGATCAGAAGTTCCTATAC
配列番号19:第16-3
AGAAGGAATGGGAGTTGCCGCCAGATTCTGACATGGATCTGAATCTGATTGAGCAGGCACCCCTGACCGTGGCCGAGAAGCTGCAGCGCGACTTTCTGACGGAATGGCGCCGTGTGAGTAAGGCCCCGGAGGCCCTTTTCTTTGTGCAAT
配列番号20:第16-4
CCGCGGTAAATTCTCTGAATCAGTTTTTCGCGAATCTGACTCAGGAAACGTCCCAAAACCATGGATTTCACCCCGGTGGTTTCCACGAGCACGTGCATGTGGAAGTAGCTCTCTCCCTTCTCAAATTGCACAAAGAAAAGGGCCTCCGGGGCCT
配列番号21:第16-5
CGAAAAACTGATTCAGAGAATTTACCGCGGGATCGAGCCGACTTTGCCAAACTGGTTCGCGGTCACAAAGACCAGAAATGGCGCCGGAGGCGGGAACAAGGTGGTGGATGAGTGCTACATCCCCAATTACTTGCTCCCCAAAACCCAGCCTGAG
配列番号22:第16-6
TACTGGTTGGAAGAAAGACCTCTATGGTCTCCCTGCTCCTGCGTCTGCGACACGTGCGTCAGATGCTGCGCCACCAACCGTTTACGCTCCGTGAGATTCAAACAGGCGCTTAAATACTGTTCCATATTAGTCCACGCCCACTGGAGCTCAGGCTGGGTTTTGGGGAGCAAGTAATT
配列番号23:第1-F
TAGCACCTGCATGCAAGCTTGCCTGCAGGCA
配列番号24:第1-R
TAGCACCTGCGCATCTGGGCCCTTAAGGATATC
配列番号25:第2-F
TAGGGTCTCGCCAGCCGGCC
配列番号26:第2-R
TAGGGTCTCCTTCCCAATAGACCCCGCA
配列番号27:第3-F
TAGCACCTGCATGCGGAACCAAGCTGGAGTG
配列番号28:第3-R
TAGCACCTGCGCATTGTCCCTGCCAGTGG
配列番号29:第4-F
TAGGGTCTCGGACACGTTGCGATACTGGT
配列番号30:第4-R
TAGGGTCTCCCACGAGCCCACGG
配列番号31:第5-F
TAGCACCTGCATGCCGTGGTGCTTGTAGGTTAC
配列番号32:第5-R
TAGCACCTGCGCATGAGCGCGGACGC
配列番号33:第6-F
TAGGGTCTCGGCTCGGGGGTGGT
配列番号34:第6-R
TAGGGTCTCCTTGCCGCGCGTTTCTC
配列番号35:第7-F
TAGCACCTGCATGCGCAAACGCTCTGCAACAAGA
配列番号36:第7-R
TAGCACCTGCGCATGTCCGCCAGGTGC
配列番号37:第8-F
TAGGGTCTCGGGACATTATCTTCCCCGAAC
配列番号38:第8-R
TAGGGTCTCCGTGGCGGCGGC
配列番号39:第9-F
TAGCACCTGCATGCCCACCCACGGACGA
配列番号40:第9-R
TAGCACCTGCGCATGAGGGAGCGCAGAGA
配列番号41:第10-F
TAGGGTCTCGCCTCACCCGCAGCTG
配列番号42:第10-R
TAGGGTCTCCGACTAAAAAATGACGTAACGGTTAAAGTC
配列番号43:第11-F
TAGCACCTGCATGCAGTCCTATATATACTCGCTCTGTACT
配列番号44:第11-R
TAGCACCTGCGCATGGAGCTATGCTAACCAGC
配列番号45:第12-F
TAGGGTCTCGCTCCGAGTATGCGTGTCA
配列番号46:第12-R
TAGGGTCTCCGTAGTTGTAGTATATCCACTCTCTCA
配列番号47:第13-F
TAGCACCTGCATGCCTACTACACAGAGCGAGCT
配列番号48:第13-R
TAGCACCTGCGCATGCACAGCACCACAATATTGTTCA
配列番号49:第14-F
TAGCACCTGCATGCGTGCTGCAGTTACTGTGCT
配列番号50:第14-R
TAGCACCTGCGCATTAGCGAGGTAAGCACTTACTCT
配列番号51:第15-F
TAGGGTCTCGGCTAGTTTCTGTGGATTCACTAGA
配列番号52:第15-R
TAGGGTCTCCCCTGGACATCCAGGTGA
配列番号53:第16-F
TAGGGTCTCGCAGGTACATCTACGGATTACGT
配列番号54:第16-R
TAGGGTCTCCCTGCTCCTGCGTCTG
配列番号55:第17-F
TAGCACCTGCATGCGCAGAACAAAGAGAATCAGAATCC
配列番号56:第17-R
TAGCACCTGCGCATGGTGAGTTCAAATTTGAACATCCG
配列番号57:第18-F
TAGGGTCTCGCACCCGCCGTCTG
配列番号58:第18-R
TAGGGTCTCCCGAGGGCCGCG
配列番号59:第19-F
TAGCACCTGCATGCCTCGAGCACGACAAAGC
配列番号60:第19-R
TAGCACCTGCGCATTGACTTGAATGTTAAAGAGCTTGAAGTTGA
配列番号61:第20-F
TAGGGTCTCGGTCAAAGAGGTCACGCAGA
配列番号62:第20-R
TAGGGTCTCCTTGGTTGTCCTGATTTCCTCTTC
配列番号63:第21-F
TAGCACCTGCATGCCCAATCCCGTGGCTAC
配列番号64:第21-R
TAGCACCTGCGCATGCATATGATACACTTGATGTACTGC
配列番号65:第22-F
TAGGGTCTCGATGCCAAGTACGCCCCCT
配列番号66:第22-R
TAGGGTCTCCCTCCCGGGCTGTAGT
配列番号67:ITR標的プライマー(フォワード)
GGAACCCCTAGTGATGGAGTT
配列番号68:ITR標的プライマー(リバース)
CGGCCTCAGTGAGCGA
配列番号69:CMV標的プライマー(フォワード)
CATCAATGGGCGTGGATAGC
配列番号70:CMV標的プライマー(リバース)
GGAGTTGTTACGACATTTTGGAAA
配列番号71:Ampr遺伝子領域標的プライマー(フォワード)
TTGATCGTTGGGAACCGGAG
配列番号72:Ampr遺伝子領域標的プライマー(リバース)
TTGTTGCCGGGAAGCTAGAG
Claims (51)
- 枯草菌においてプラスミド複製を促進する核酸配列と、
ウイルスベクターを構成するのに必要な核酸配列のうちの少なくとも1つと、
を含むプラスミド。 - 前記ウイルスベクターを構成するのに必要な核酸配列は、
前記ウイルスのカプシドタンパク質をコードする核酸配列と、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列と、
前記ウイルスの2つの末端反復配列と、
ヘルパー遺伝子をコードする核酸配列と、
を含む、請求項1に記載のプラスミド。 - 前記ウイルスのカプシドタンパク質をコードする核酸配列、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列、
前記ウイルスの2つの末端反復配列、および
ヘルパー遺伝子をコードする核酸配列
のうちの少なくとも2つを含む、請求項1に記載のプラスミド。 - 前記ウイルスのカプシドタンパク質をコードする核酸配列、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列、
前記ウイルスの2つの末端反復配列、および
ヘルパー遺伝子をコードする核酸配列
のうちの少なくとも3つを含む、請求項1に記載のプラスミド。 - 前記ウイルスのカプシドタンパク質をコードする核酸配列と、
前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列と、
前記ウイルスの2つの末端反復配列と、
ヘルパー遺伝子をコードする核酸配列と、
を含む、請求項1に記載のプラスミド。 - 前記ウイルスベクターを構成するのに必要な核酸配列が、約10kb以上である、請求項1~5のいずれか一項に記載のプラスミド。
- 前記カプシドタンパク質をコードする核酸配列、前記ゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列および前記ヘルパー遺伝子の少なくとも1つが、前記2つの末端反復配列に挟まれる領域の外にある、請求項2~6のいずれか一項に記載のプラスミド。
- 枯草菌においてプラスミド複製を促進する前記核酸配列が、枯草菌において作動する複製起点を含む、請求項1~7のいずれか一項に記載のプラスミド。
- 大腸菌においてプラスミドを増幅する核酸配列をさらに含む、請求項1~8のいずれか一項に記載のプラスミド。
- 前記ウイルスのカプシドタンパク質をコードする核酸配列が、L1、L2、L3、L4、L5、capおよびgagのうちの少なくとも1つを含む、請求項2~9のいずれか一項に記載のプラスミド。
- 前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列が、E1A、E1B、E2A、E2B、E4、rep、ψ、APP、MAAP、polおよびrevのうちの少なくとも1つを含む、請求項2~10のいずれか一項に記載のプラスミド。
- 前記末端反復配列が、末端逆位反復配列(ITR)または長鎖末端反復配列(LTR)である、請求項2~11のいずれか一項に記載のプラスミド。
- 前記ヘルパー遺伝子が、E1A、E1B、E2A、E4、VA、env、tat、RPE、PPT、PREおよびproのうちの少なくとも1つを含む、請求項2~12のいずれか一項に記載のプラスミド。
- 前記ウイルスのカプシドタンパク質をコードする核酸配列および前記ウイルスのゲノムを転写および複製するタンパク質をコードする核酸配列のうちの少なくとも1つが、アデノウイルスの血清型1~52またはアデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、請求項2~13のいずれか一項に記載のプラスミド。
- 前記プラスミドが、前記ウイルスの全ゲノムのうち少なくとも一部の遺伝子の配列を含まない、請求項1~14のいずれか一項に記載のプラスミド。
- 前記ウイルスが、アデノウイルス、アデノ随伴ウイルス、レンチウイルス、レトロウイルスまたはセンダイウイルスである、請求項1~15のいずれか一項に記載のプラスミド。
- 前記ウイルスが、アデノ随伴ウイルスまたはレンチウイルスである、請求項1~15のいずれか一項に記載のプラスミド。
- 前記ウイルスが、アデノ随伴ウイルスである、請求項1~15のいずれか一項に記載のプラスミド。
- 前記末端反復配列が、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する末端逆位反復配列(ITR)である、請求項2~18のいずれか一項に記載のプラスミド。
- 5’ITRおよび3’ITRの間に上流からプロモーター、所望の遺伝子およびターミネーターを含む、請求項19に記載のプラスミド。
- 前記ヘルパー遺伝子が、E1A、E1B、E2A、E4、およびVAのうちの少なくとも1つを含む、請求項2~20のいずれか一項に記載のプラスミド。
- 前記ヘルパー遺伝子が、E2A、E4、およびVAを含む、請求項2~20のいずれか一項に記載のプラスミド。
- 前記ヘルパー遺伝子のそれぞれが、アデノウイルスの血清型1~52およびその改変体のいずれかに由来する、請求項2~22のいずれか一項に記載のプラスミド。
- 前記ウイルスのゲノムをパッケージング、転写および複製するタンパク質をコードする核酸配列が、repを含む、請求項2~23のいずれか一項に記載のプラスミド。
- 前記repが、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、請求項24に記載のプラスミド。
- 前記ウイルスのカプシドタンパク質をコードする核酸配列が、capを含む、請求項2~25のいずれか一項に記載のプラスミド。
- 前記capが、アデノ随伴ウイルスの血清型1~12およびその改変体のいずれかに由来する、請求項26に記載のプラスミド。
- 前記ウイルスの2つの末端反復配列の間に所望の遺伝子を含む、請求項2~27のいずれか一項に記載のプラスミド。
- 前記所望の遺伝子が、2~100個の遺伝子である、請求項28に記載のプラスミド。
- 前記所望の遺伝子が、10~100個の遺伝子である、請求項28に記載のプラスミド。
- 前記所望の遺伝子が、プロモーター配列を含む、請求項28~30のいずれか一項に記載のプラスミド。
- 前記プラスミドおよびプロデューサー細胞が、一緒になって前記ウイルスベクターを構成するのに必要な核酸配列を含む、請求項1~31のいずれか一項に記載のプラスミド。
- 前記プラスミドを導入したプロデューサー細胞から生産される全ウイルスベクター粒子のうち、核酸を含まないウイルスベクター粒子が65%以下である、請求項1~32のいずれか一項に記載のプラスミド。
- プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、請求項1~33のいずれか一項に記載のプラスミド。
- プロデューサー細胞に導入した場合に、生産される全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、請求項1~34のいずれか一項に記載のプラスミド。
- CCC(covalently closed circular)純度が、80%以上である、請求項1~35のいずれか一項に記載に記載のプラスミド。
- 所望の遺伝子を発現するための、請求項1~36のいずれか一項に記載のプラスミドを含む組成物であって、前記所望の遺伝子は前記プラスミド上で前記ウイルスの2つの末端反復配列の間に配置される、組成物。
- 請求項1~32のいずれか一項に記載の核酸配列を作動可能に連結するステップを含む、請求項1~36のいずれか一項に記載のプラスミドを生産する方法。
- 請求項38に記載の方法によって生産されるプラスミド含有組成物。
- プラスミドのCCC(covalently closed circular)純度が、80%以上である、請求項39に記載のプラスミド含有組成物。
- 請求項1~36のいずれか一項に記載のプラスミドを作製するためのキットであって、
枯草菌においてプラスミド複製を促進する核酸配列と、
ウイルスを構成するのに必要な核酸配列と、
を含む少なくとも1つの核酸を含む、キット。 - 請求項1~36のいずれか一項に記載のプラスミドを含む、ウイルスベクターを調製するための組成物。
- 請求項1~36のいずれか一項に記載のプラスミドを用いてウイルスベクターを生産するステップを含む、ウイルスベクターを調製するための方法。
- 前記プラスミドに含まれる核酸の少なくとも一部が、前記プラスミドを導入したプロデューサー細胞の染色体に組み込まれる、請求項43に記載の方法。
- 請求項1~36のいずれか一項に記載のプラスミドを用いて生産される、または請求項43または44に記載の方法を用いて生産される、ウイルスベクター。
- 請求項1~36のいずれか一項に記載のプラスミドを用いて生産される、または請求項43または44に記載の方法を用いて生産される、ウイルスベクター含有組成物。
- 全ウイルスベクター粒子のうち核酸を含まないウイルスベクター粒子が65%以下である、請求項46に記載の組成物。
- 全ウイルスベクター粒子のうち、全ての所望の遺伝子を含む核酸を含むウイルスベクター粒子が90%以上である、請求項46または47に記載の組成物。
- 全ウイルスベクター粒子のうち、所望の核酸以外の前記プラスミド由来の核酸を含むウイルスベクター粒子が2%以下である、請求項46~48のいずれか一項に記載の組成物。
- 請求項1~36のいずれか一項に記載のプラスミドを含む枯草菌または大腸菌。
- 請求項1~36のいずれか一項に記載のプラスミドが導入されたプロデューサー細胞であって、前記プラスミドに含まれる核酸の少なくとも一部が、前記プロデューサー細胞の染色体に組み込まれている、プロデューサー細胞。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3200835A CA3200835A1 (en) | 2020-11-04 | 2021-11-02 | Integrative plasmid |
JP2022506963A JP7329296B2 (ja) | 2020-11-04 | 2021-11-02 | 統合型プラスミド |
EP21889200.8A EP4242316A1 (en) | 2020-11-04 | 2021-11-02 | Integrative plasmid |
CN202180074504.6A CN116391027A (zh) | 2020-11-04 | 2021-11-02 | 整合型质粒 |
IL302580A IL302580A (en) | 2020-11-04 | 2021-11-02 | Integrative plasmid |
KR1020237018437A KR20230116802A (ko) | 2020-11-04 | 2021-11-02 | 통합형 플라스미드 |
AU2021375125A AU2021375125A1 (en) | 2020-11-04 | 2021-11-02 | Integrative plasmid |
JP2022169231A JP2022183360A (ja) | 2020-11-04 | 2022-10-21 | 統合型プラスミド |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-184491 | 2020-11-04 | ||
JP2020184491 | 2020-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022097647A1 true WO2022097647A1 (ja) | 2022-05-12 |
Family
ID=81457251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/040411 WO2022097647A1 (ja) | 2020-11-04 | 2021-11-02 | 統合型プラスミド |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4242316A1 (ja) |
JP (2) | JP7329296B2 (ja) |
KR (1) | KR20230116802A (ja) |
CN (1) | CN116391027A (ja) |
AU (1) | AU2021375125A1 (ja) |
CA (1) | CA3200835A1 (ja) |
IL (1) | IL302580A (ja) |
WO (1) | WO2022097647A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908845A (en) | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
WO2001090392A1 (fr) | 2000-05-26 | 2001-11-29 | Sumitomo Pharmaceuticals Company, Limited | Nouveau vecteur d'adenovirus recombinant a effets secondaires reduits |
JP2002528049A (ja) * | 1998-07-22 | 2002-09-03 | イミューソル インコーポレイテッド | 実質的に完全なリボザイムライブラリー |
WO2015111248A1 (ja) | 2014-01-21 | 2015-07-30 | 学校法人慶應義塾 | 単位dna組成物の調製方法及びdna連結体の作製方法 |
JP2018093024A (ja) | 2016-12-01 | 2018-06-14 | 三菱電機株式会社 | 半導体装置および電力変換装置 |
JP2020184491A (ja) | 2019-05-09 | 2020-11-12 | コイズミ照明株式会社 | 照明器具および照明システム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5945168B2 (ja) * | 2012-06-08 | 2016-07-05 | 花王株式会社 | 組換え微生物及びそれを用いたポリ−γ−グルタミン酸の製造方法 |
JP6750830B2 (ja) * | 2015-04-07 | 2020-09-02 | 国立大学法人東京工業大学 | 形質転換細胞の製造方法 |
JP6731232B2 (ja) * | 2015-10-28 | 2020-07-29 | 花王株式会社 | タンパク質又はポリペプチドの製造方法 |
-
2021
- 2021-11-02 CA CA3200835A patent/CA3200835A1/en active Pending
- 2021-11-02 JP JP2022506963A patent/JP7329296B2/ja active Active
- 2021-11-02 IL IL302580A patent/IL302580A/en unknown
- 2021-11-02 KR KR1020237018437A patent/KR20230116802A/ko unknown
- 2021-11-02 EP EP21889200.8A patent/EP4242316A1/en active Pending
- 2021-11-02 AU AU2021375125A patent/AU2021375125A1/en active Pending
- 2021-11-02 CN CN202180074504.6A patent/CN116391027A/zh active Pending
- 2021-11-02 WO PCT/JP2021/040411 patent/WO2022097647A1/ja unknown
-
2022
- 2022-10-21 JP JP2022169231A patent/JP2022183360A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908845A (en) | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
JP2002528049A (ja) * | 1998-07-22 | 2002-09-03 | イミューソル インコーポレイテッド | 実質的に完全なリボザイムライブラリー |
WO2001090392A1 (fr) | 2000-05-26 | 2001-11-29 | Sumitomo Pharmaceuticals Company, Limited | Nouveau vecteur d'adenovirus recombinant a effets secondaires reduits |
WO2015111248A1 (ja) | 2014-01-21 | 2015-07-30 | 学校法人慶應義塾 | 単位dna組成物の調製方法及びdna連結体の作製方法 |
JP2018093024A (ja) | 2016-12-01 | 2018-06-14 | 三菱電機株式会社 | 半導体装置および電力変換装置 |
JP2020184491A (ja) | 2019-05-09 | 2020-11-12 | コイズミ照明株式会社 | 照明器具および照明システム |
Non-Patent Citations (15)
Title |
---|
ANAGNOSTOPOULOU, C.SPIZIZEN, J., J. BACTERIOL., vol. 81, 1961, pages 741 - 746 |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1995, WILEY INTERSCIENCE PUBLISHERS, article "DNA Cloning 1: Core Techniques, A Practical Approach" |
IMANAKA, T. ET AL., J. GEN. MICROBIOI., vol. 130, 1984, pages 1399 - 1408 |
IMANAKA, T. ET AL., J.GEN.MICROBIOI, vol. 130, 1984, pages 1399 - 1408 |
ISSAY NARUMT ET AL., BIOTECHNOLOGY LETTERS, vol. 17, no. 5, May 1995 (1995-05-01), pages 475 - 480 |
ITAYA, M., BIOSCI. BIOTECHNOL. BIOCHEM., vol. 63, 1999, pages 602 - 604 |
JANNIERE, L.A. GRUSSS. D. EHRLICH: "Plasmids", 1993, AMERICAN SOCIETY FOR MICROBIOLOGY, article "Bacillus subtilis and other gram-positive bacteria: biochemistry, physiology and molecular genetics", pages: 625 - 644 |
JOURNAL OF BACTERIOLOGY, vol. 183, pages 5453 - 5458 |
MOLEKULIARNAIA GENETIKA, no. 5, 1 May 1991 (1991-05-01), pages 26 - 29 |
P TRIEU-CUOT ET AL., EMBO J., vol. 4, no. 13A, 16 December 1985 (1985-12-16), pages 3583 - 3587 |
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", vol. 1, 1989, COLD SPRING HARBOR LABORATORY PRESS, pages: 42 - 45 |
SWINFIELD, T. J. ET AL., GENE, vol. 87, 1990, pages 79 - 90 |
TANAKA, TOGRA, M., FEBS LETT., vol. 422, 1998, pages 243 - 246 |
TSUGE, K.SATO, Y.KOBAYASHI, Y.GONDO, M.HASEBE, M.TOGASHI, T.TOMITA, M.ITAYA, M.: "Method of preparing an equimolar DNA mixture for one-step DNA assembly of over 50 fragments", SCIENTIFIC REPORTS, vol. 5, 2015, pages 10655, XP055369781, DOI: 10.1038/srep10655 |
YANSURA, D.HENNER, D., J. PRO. NATL. ACAD. SCI, USA, vol. 81, 1984, pages 439 - 443 |
Also Published As
Publication number | Publication date |
---|---|
JP2022183360A (ja) | 2022-12-08 |
IL302580A (en) | 2023-07-01 |
EP4242316A1 (en) | 2023-09-13 |
JP7329296B2 (ja) | 2023-08-18 |
AU2021375125A1 (en) | 2023-06-15 |
JPWO2022097647A1 (ja) | 2022-05-12 |
CA3200835A1 (en) | 2022-05-12 |
CN116391027A (zh) | 2023-07-04 |
KR20230116802A (ko) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016362317B2 (en) | Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use | |
US20200165632A1 (en) | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION | |
US20220307018A1 (en) | ENGINEERED GUIDE RNA FOR THE OPTIMIZED CRISPR/Cas12f1 SYSTEM AND USE THEREOF | |
CA3026055A1 (en) | Novel crispr enzymes and systems | |
JP7104263B1 (ja) | 枯草菌におけるウイルスベクタープラスミド生産 | |
JP2021528959A (ja) | 細胞内で存続する遺伝子送達のためのベクター | |
JP2023503455A (ja) | アデノ随伴ウイルスベクター変種 | |
CN113454232A (zh) | 封闭端dna(cedna)产生中对rep蛋白活性的调节 | |
CA3157063A1 (en) | Dual viruses and dual oncolytic viruses and methods of treatment | |
WO2023214578A1 (ja) | ウイルス由来構築物プラスミドライブラリーおよびその構築 | |
WO2022097647A1 (ja) | 統合型プラスミド | |
WO2023214579A1 (ja) | ウイルス由来構築物プラスミド | |
CN115397844A (zh) | 生长因子恢复 | |
WO2023220386A1 (en) | Adeno-associated viral vectors for targeting brain microvasculature | |
WO2023147558A2 (en) | Crispr methods for correcting bag3 gene mutations in vivo | |
WO2023245092A2 (en) | STRESS EDITING OF CAMKIIδ | |
WO2023220649A2 (en) | Effector protein compositions and methods of use thereof | |
WO2023220287A1 (en) | Adeno-associated viral vectors for targeting deep brain structures | |
Velthuis | Large virus for an even bigger task: can the mimivirus close the gene-therapy vector void? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022506963 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21889200 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3200835 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021889200 Country of ref document: EP Effective date: 20230605 |
|
ENP | Entry into the national phase |
Ref document number: 2021375125 Country of ref document: AU Date of ref document: 20211102 Kind code of ref document: A |